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1 Introduction 
LBI-HTA published the report “Quality of care in oncology and its meas-
urement” in 2011 where international efforts in indicator development are 
discussed. Therein 17 indicator sets for measuring quality in oncological 
care were presented as examples. 
In order to give clinical practice a hands on tool book in the area of cancer 
care quality indicators, this compendium provides details about generic (i.e. 
not cancer type specific) process indicators (i.e. not structure or outcome) 
from this pool of 17 oncological indicator sets. 
Table 1 gives an overview of this pool of 17 indicator sets. 
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Table 1: Pool of indicator sets for this compendium 
Source Country Content covered by indicator set 
KRZYZANOWSKA (2011) Canada, 
Ontario 
Population-level indicators to measure the quality of cancer care for women 
NQF (2009) USA National Quality Forum 
National Voluntary Consensus Standards for Quality of Cancer Care: Breast and Colorectal Cancer, Symptom Management and End-of-Life Care 
AHRQ (2011), AHRQ (2009) USA Agency for Healthcare Research and Quality 
National Healthcare Quality Report, Indicators for Breast and Colorectal Cancer 
LORENZ (2006) USA Agency for Healthcare Research and Quality 
Cancer Care Quality Measures: Symptoms and End-of-Life Care 
PATWARDHAN (2007) USA Agency for Healthcare Research and Quality 
Cancer Care Quality Measures: Diagnosis and Treatment of Colorectal Cancer 
MOHER (2004) USA Agency for Healthcare Research and Quality 
Cancer Care Quality Measures: Breast Cancer 
MALIN (2006) – Breast cancer USA American Society of Clinical Oncology 
National Initiative for Cancer Care Quality: Breast Cancer 
MALIN (2006) – Colorectal cancer USA American Society of Clinical Oncology 
National Initiative for Cancer Care Quality: Colorectal Cancer 
ASCO - NCCN (2007) USA American Society of Clinical Oncology - National Comprehensive Cancer Network  
Breast Cancer, Colorectal Cancer 
ASCO/ QOPI (2011) USA American Society of Clinical Oncology  
Quality Oncology Practice Initiative: wide range of indicators 
AMA/ PCPI (2011) USA American Medical Association 
Physican Consortium for Performance Improvement: wider range of indicators 
GREENBERG (2005) Canada, 
Ontario 
Cancer Care Ontario 
Cancer Quality Council of Ontario  
Development of a set of strategy-based system-level cancer care performance indicators 
CSQI (2011) Canada, 
Ontario 
Cancer Quality Council of Ontario 
Ontario Cancer System Quality Index 
NCASP (2011) England National Clinical Audit Support Programme: 
example indicators from the Bowel Cancer Audit 2010 
AQUA (2011) Germany Institut fu¨r angewandte Qualita¨tsfo¨rderung und Forschung im Gesundheitswesen AQUA 
External inpatient quality assurance: Breast cancer surgery 
NPK Monitor (2009) Netherlands National Cancer Plan 
NPK Monitor Card 
VLAYEN (2011) – Rectal cancer Belgium Belgian Healthcare Knowledge Center KCE 
Indicators rectal cancer 
VLAYEN (2011) – Breast cancer Belgium Belgian Healthcare Knowledge Center KCE 
Indicators breast cancer 
VLAYEN (2011) – Testis cancer Belgium Belgian Healthcare Knowledge Center KCE 
Indicators testis cancer 
NIP (2011) Denmark National Indicator Project 
Lung Cancer 
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2 Method and indicator selection 
The focus of this compendium lies on processes after a confirmed diagnosis 
of cancer. Therefore indicators for preventive care including screening are 
not covered. 
Generic process indicators that were found in at least two of the 17 indicator 
sets are subsequently described in greater detail. 
From the indicator pool described in table 1 above, the following indicators 
qualify as generic (i.e. not cancer type specific) for process quality. 
Krzyzanowska (2011) 
Population-level indicators to measure the quality of cancer care for women selected for evaluation by expert panel 
Catego-
ry 
No. Indicator name Definition 
 
Waiting 
time 
3. Wait times for surgery (breast, co-
lon, ovary, uterus and cervical can-
cers) 
This indicator looks at how long patients wait for cancer sur-
gery, measuring the time between the initial consultation with 
the surgeon and the date the surgery was done, reporting both 
the median (the time by which 50% of patients underwent sur-
gery) and the 90th percentile (the time by which 90% of pa-
tients underwent surgery). 
End-of-
life 
26. Death in an acute-care bed (lung, 
colorectal, breast or gynecological 
cancers) 
This indicator measures the percentage of patients with cancer 
who died in an acute-care bed in hospital. 
End-of-
life 
27. Emergency department visit in the 
last two weeks of life (lung, colorec-
tal, breast or gynecological cancers)
This indicator measures the proportion of patients who died of 
cancer who had at least one emergency department visit in the 
last 2 weeks of life. 
End-of-
life 
28.  Chemotherapy in the last two weeks 
of life (lung, colorectal, breast or 
gynecological cancers) 
This indicator measures the percentage of cancer patients who 
received chemotherapy in the two weeks before they died 
End-of-
life 
29. Home care visits in the last 6 
months of life (lung, colorectal, 
breast or gynecological cancers) 
This indicator measures the percentage of cancer patients who 
died who received one of more home care visits in the last 6 
months of life. 
End-of-
life 
30. Physician house calls in the last two 
weeks of life (lung, colorectal, 
breast or gynecological cancers) 
This indicator measures the percentage of patients who had one 
or more physician house calls in the last two weeks of their lives.
Source: Krzyzanowska (2011), table 2 
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NQF (2009) 
National Quality Forum NQF: Specifications of the National Voluntary Consensus Standards for Quality of 
Cancer Care 
Category Symptom Management and End-of-Life Care 
 
Details 
End-of-life Family Evaluation of Hospice Care Survey of family members of all patients en-
rolled in a hospice program, who died following 
care. 
End-of-life Comfortable dying Patients whose pain was brought under control 
within 48 hours of admission to hospice. 
End-of-life Chemotherapy in the last 14 days of life  
End-of-life More than one emergency room visit in the last 30 days 
of life 
 
End-of-life More than one hospitalization in the last 30 days of life  
End-of-life Intensive care unit admission in the last 30 days of life  
End-of-life Dying in an acute care setting  
End-of-life Not admitted to hospice  
End-of-life Admitted to hospice for less than three days  
Source: National Quality Forum (2009), appendix A 
 
Indikatoren AHRQ (2011), AHRQ (2009) 
Agency for Health Research and Quality: Quality measures for effectiveness 
of care: colorectal, breast, cervical and other cancer: all process indicators 
pertinent to screening. 
Source: AHRQ (2011), appendix „Measure Specification“, only online: 
www.AHRQ.gov/qual/qrdr10/measurespec/cancer.htm 
Indikatoren Lorenz (2006) 
Agency for Healthcare Research and Quality AHQR Review: Measure Sets 
for Symptoms and End-of-Life Care 
Lorenz (2006) – RAND Health QA Tools  
Research and Development Corp. RAND 
Category  Indicator 
Supportive Cancer 
Care: Pain 
Pain assessment 
 
Regular assessment of pain 
 
Supportive Cancer 
Care: Pain 
Pain treatment Responsive pain treatment 
Supportive Cancer 
Care: Dyspnea 
Dyspnea treatment Treatment of dyspnea caused by 
hypoxia 
Source: Lorenz (2006): appendix F1, F2 
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Lorenz (2006) – ACOVE 
Assessing the Care Of Vulnerable Elders ACOVE 
Category  Indicator 
 
Supportive cancer care 
Pain 
Pain assessment Routine pain assessment in expected dying 
Supportive cancer care 
Dyspnea 
Dyspnea treatment Effective dyspnea treatment in expected dying 
Supportive cancer care 
Dyspnea 
Dyspnea treatment Regular treatment and follow-up of dyspnea in expected dy-
ing 
Supportive cancer care 
Depression 
Depression assessment Regular spiritual assessment in expected dying 
Supportive cancer care 
Depression 
Depression treatment Regular assessment or treatment of depression in newly di-
agnosed cancer 
Supportive cancer care 
Depression 
Depression treatment Routine assessment or treatment of depression in sympto-
matic patients 
Supportive cancer care 
Advanced Care Planning 
ACP Assessment Regular identification of a surrogate in the outpatient set-
ting 
Supportive cancer care 
Advanced Care Planning 
ACP Assessment Regular identification of a surrogate among hospital admis-
sions with impaired cognition 
Supportive cancer care 
Advanced Care Planning 
ACP Assessment Regular assessment of preferences among inpatients with 
dementia 
Supportive cancer care 
Advanced Care Planning 
ACP Assessment Regular assessment of preferences in an ICU 
Supportive cancer care 
Advanced Care Planning 
ACP Assessment Regular patient participation in decisions to limit treatment 
Supportive cancer care 
Advanced Care Planning 
ACP Application Documentation of care preferences across venues 
Supportive cancer care 
Advanced Care Planning 
ACP Application Documentation of specific life sustaining preferences 
Supportive cancer care 
Advanced Care Planning 
ACP Follow-up Consistency of preferences with use of ventilatory support 
Supportive cancer care: 
Advanced Care Planning 
ACP Follow-up Care consistency with documented care preferences 
Source: Lorenz (2006): appendix F1, F2, F3, F4 
 
Lorenz (2006) – Dana-Farber Cancer Institute 
Category  Indicator 
 
Supportive cancer 
care 
Advanced Care Plan-
ning 
ACP Follow-up 
 
Late life rate of emergency care: Emer-
gency room visit in the last month of life. 
Source: Lorenz (2006): appendix F4 
 
Lorenz (2006) – CCNS 
Cancer Care Nova Scotia CCNS 
Category  Indicator 
 
Supportive cancer 
care 
Pain 
Pain treatment Effective treatment for painful bony me-
tastasis 
Source: Lorenz (2006), appendix F1 
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Lorenz (2006) – Cancer Care Ontario 
Cancer Care Ontario 
Category  Indicator 
 
Supportive cancer care 
Advanced Care Planning 
ACP Follow-up 
 
Late life rate of emergency care: Emer-
gency room visit in the last month of 
life. 
Supportive cancer care 
Advanced Care Planning 
ACP Follow-up 
 
Chemotherapy in the last 14 days of life. 
Supportive cancer care 
Advanced Care Planning 
ACP Follow-up 
 
Admission to hospice. 
Supportive cancer care 
Advanced Care Planning 
ACP Follow-up 
 
Site of death. 
Source: Lorenz (2006), appendix F4 
 
Lorenz (2006) – Georgia Cancer Coalition 
Georgia Cancer Coalition GCC 
Category  Indicator 
 
Supportive cancer care 
Pain 
Pain assessment Routine assessment of pain. 
Source: Lorenz (2006): appendix F1 
 
Lorenz (2006) – VHA 
VHA Inc., Irving, Texas 
Category  Indicator 
 
Supportive cancer care 
Pain 
Pain assessment Regular ICU pain assessment 
Supportive cancer care 
Pain 
Pain follow-up Effective treatment of pain in the ICU 
Supportive cancer care 
Advanced Care Planning
ACP Assessment Regular identification of a surrogate in the 
ICU. 
Supportive cancer care 
Advanced Care Planning
ACP Assessment Regular assessment of advance directives 
for ICU patients 
Supportive cancer care 
Advanced Care Planning
ACP Assessment Regular assessment of specific resuscitation 
preferences in the ICU 
Supportive cancer care 
Advanced Care Planning
ACP Assessment Regular clinician-patient-family communi-
cation in the ICU 
Source: Lorenz (2006): appendix F1, F4 
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Lorenz (2006) – UHC 
University Health Consortium UHC 
Category  Indicator 
 
Supportive cancer 
care 
Pain 
Pain assessment Routine inpatient pain assessment 
Supportive cancer 
care 
Pain 
Pain assessment Routine inpatient pain assessment with a 
numeric scale 
Supportive cancer 
care 
Pain 
Pain treatment Regular prophylaxis of opiate-induced 
constipation 
Supportive cancer 
care 
Pain 
Pain follow-up Timely treatment of inpatient pain 
Supportive care 
Dyspnea 
Dyspnea assessment Regular dyspnea assessment 
Supportive care 
Dyspnea 
Dyspnea follow-up Timely treatment of inpatient dyspnea 
Supportive care 
Depression 
Depression assess-
ment 
Regular assessment for psychosocial well-
being 
Supportive care 
Advance Care Plan-
ning 
ACP assessment Regular family meetings among hospital-
ized patients 
Supportive care 
Advance Care Plan-
ning 
ACP assessment Timely and effective discharge planning 
Source: Lorenz (2006): appendix F1, F2, F3, F4 
 
Lorenz (2006) – NHPCO 
National Hospice and Palliative Care Organisation NHPCO 
Category  Indicator 
 
Supportive cancer 
care 
Pain 
Pain follow-up Timely treatment of pain in hospice 
Supportive care 
Advance Care Plan-
ning 
ACP assessment Regular assessment of preferences in 
hospice 
Supportive care 
Advance Care Plan-
ning 
ACP follow-up Safe dying in hospice (survey of care-
givers after death) 
Source: Lorenz (2006): appendix F1, F4 
 
Patwardhan (2007) 
Agency for Healthcare Research and Quality AHRQ Review: Selected qual-
ity measures for the diagnosis and treatment of colorectal cancer: All indica-
tors specific for colorectal cancer. 
Source: Patwardhan (2007), table 3 
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Moher (2004) 
Agency for Healthcare Research and Quality AHRQ Review: Listing of 
Quality Indicators Used to Measure Adherence to Standards of Breast Can-
cer Care: All indicators breast cancer specific. 
Source: Moher (2004), appendix G 
 
Malin (2006) 
Malin (2006) – Breast Cancer 
Results of the National Initiative for Cancer Care Quality: breast cancer care 
measures with less than 85% adherence by metropolitan statistical area: All 
indicators breast cancer specific. 
Source: http://jco.ascopubs.org/content/24/4/626/T9.expansion.html - table 5 
 
Malin (2006) – Colorectal cancer 
Results of the National Initiative for Cancer Care Quality: colorectal cancer 
care measures with less than 85% adherence by metropolitan statistical area: 
All indicators specific for colorectal cancer. 
Source: http://jco.ascopubs.org/content/24/4/626/T10.expansion.html - table 6 
 
ASCO – NCCN (2007) 
American Society of Clinical Oncology ASCO and National Comprehensive 
Cancer Care Network NCCN, Indicators for Breast, Colon, Colorectal and 
Rectal Cancer: All indicators non generic. 
Source: breast and colon – table 1, colorectum – table 2, rectum – table 3: 
www.asco.org/ASCO/Downloads/Cancer%20Policy%20and%20Clinical%20Affair
s/NCCN/ASCO%20NCCN%20Quality%20Measures%20table%20web%20posting
%20with%20CoC%200507.pdf  
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ASCO/ QOPI (2011) 
American Society of Clinical Oncology ASCO– Quality Oncology Practice 
Initiative QOPI: Summary of Measures 
Category Core 
Generic Process 1. Pathology report confirming malignancy* 
Generic Process 2. Staging documented within one month of first office visit* 
Generic Process 3. Pain assessed by second office visit  
Generic Process 4. Pain intensity quantified by second office visit  
Generic Process 5. Plan of care for moderate/severe pain documented  
Generic Process 7. Effectiveness of narcotic assessed on visit following prescription  
Generic Process 8. Constipation assessed at time of narcotic prescription or following visit  
Generic Process 9. Documented plan for chemotherapy, including doses, route, and time intervals*  
Generic Process 10. Chemotherapy intent (curative vs. palliative) documented*  
Generic Process 11. Chemotherapy intent discussion with patient documented  
Generic Process 12. Number of chemotherapy cycles documented  
Generic Process 14. Signed patient consent for chemotherapy  
Generic Process 15. Patient consent documented in practitioner note  
Generic Process 17. Chemotherapy treatment summary completed within 3 months of chemotherapy end  
Generic Process 18. Chemotherapy treatment summary provided to patient within 3 months of chemotherapy end  
Generic Process 19. Chemotherapy treatment summary provided or communicated to practitioner(s) within 3 
months of chemotherapy end  
Generic Process 24. Patient emotional well-being assessed by the second office visit*  
Generic Process 25. Action taken to address problems with emotional well-being by the second office visit  
Domain Specific Modules 
Symptom/Toxicity Management – Chemotherapy-Related 
Generic Process 26. Serotonin antagonist prescribed with moderate/high emetic risk chemotherapy  
Generic Process 27. Corticosteroids and serotonin antagonist prescribed with moderate/high emetic risk chemother-
apy*  
Generic Process 28. Aprepitant prescribed with high emetic risk chemotherapy  
Generic Process 30. Baseline iron stores documented within 90 days prior to administration of ESAs 
Generic Process 31. Hemoglobin < 10g/dL documented within 2 weeks prior to administration of ESAs  
Generic Process 33. Infertility risks discussed prior to chemotherapy with patients of reproductive age*  
Generic Process 34. Fertility preservation options discussed or referral to specialist  
Care at End-of-Life 
End-of-life 35. Pain assessed on either of the last two visits before death 
End-of-life 36. Pain intensity quantified on either of the last two visits before death 
End-of-life 37. Plan of care for moderate/severe pain documented on either of the last two visits before death 
End-of-life 39. Dyspnea assessed on either of the last two visits before death 
End-of-life 40. Dyspnea addressed on either of the last two visits before death 
End-of-life 41. Dyspnea addressed appropriately (defect-free measure, 39 and 40) 
End-of-life 42. Hospice enrollment and 43. Hospice enrollment or palliative care referral 
End-of-life 44. Hospice enrollment within 3 days of death  (Lower Score – Better) 
End-of-life 45. Hospice enrollment within 7 days of death (Lower Score – Better) 
End-of-life 45a. Hospice enrollment and enrolled more than 7 days before death (defect-free measure, 42 and 
inverse 45)* 
End-of-life 46. For patients not referred, hospice or palliative care discussed within the last 2 months of life 
End-of-life 48. Chemotherapy administered within the last 2 weeks of life  (Lower Score – Better) 
 
*Included in QOPI Certification Program 
Source: http://qopi.asco.org/Documents/QOPISpring2011MeasuresSummary_000.pdf 
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AMA/ PCPI (2011) 
American Medical Association AMA/ Physician Consortium for Performance 
Improvement PCPI Approved Quality Measures for Cancer Care 
Category Measure Topic Measure Title 
 
Generic Pro-
cess 
Oncology 
 
 Cancer Stage Documented 
 Pain Intensity Quantified-Medical On-
cology and Radiation Oncology 
 Pathology Report (QI) 
 Plan for Chemotherapy Documented 
 Plan of Care for Pain-Medical Oncology 
and Radiation Oncology 
 Treatment Summary Communication – 
Radiation Oncology 
 Treatment Summary Documented – 
Medical Oncology (QI) 
 Treatment Summary Communicated– 
Medical Oncology (QI) 
End-of-Life Palliative Care (not 
cancer specific) 
 Advance care planning 
 Dyspnea screening and management 
Source: http://www.ama-assn.org/apps/listserv/x-check/qmeasure.cgi?submit=PCPI, 
Aug. 2011 
 
Greenberg (2005) 
Selected indicators for strategy-based, system-level cancer care performance indicators 
Category Strategic goal Indicator 
 
Definition 
Generic Process Integrated IT systems Percentage of hospitals that meet volume cut-off for cancer 
services that have single view of patient results available in 
the hospital to appropriate providers that include diagnos-
tic, procedural, systemic, and radiation therapy information.
Generic Process Cancer data capture Percentage of hospitals submitting all required data on can-
cer diagnosis and treatment on time to Cancer Care Ontario 
Percentage of data by cancer service modality that is sub-
mitted to Cancer Care Ontario on time. 
Generic Process Synoptic reporting Percentage of pathology reports submitted to Cancer Care 
Ontario that are reported synoptically. 
Generic Process 
Improve meas-
urement, collec-
tion, and report-
ing of cancer 
system per-
formance 
Stage capture rate 
 
Proportion of incident cancer cases in which a cancer stage 
was identified. 
Generic Process CPOE Percentage of medical oncologists using Computerized Phy-
sician Order Entry systems. 
Generic Process Guideline application Percentage of Ontario cancer cases treated according to se-
lected Program in Evidence-Based Care (PEBC) guidelines 
(1–2 example conditions). 
Generic Process Clinical trial 
Participation 
Number of patients recruited to clinical trials for chemo-
therapy, radiotherapy, and interventions studies by hospi-
tal. 
Generic Process Cancer research 
Funding 
Percentage of Integrated Cancer Programs’ annual budgets 
devoted to cancer research funding. 
Generic Process 
Increase use of 
evidence and 
innovation in 
decision-making 
Innovation Hospitals’ self-reported environments for innovation (ques-
tionnaire). 
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Category Strategic goal Indicator 
 
Definition 
Generic Process Radiation therapy 
(RT) quality assur-
ance 
Percentage of RT facilities in compliance with Healing Arts 
Radiation Protection (HARP) guidelines. 
(Generic Proc-
ess*) 
Increase effec-
tive use of re-
sources across 
the system Patient satisfaction 
with coordination of 
care 
Oncology patient satisfaction survey results related to co-
ordination of care. 
Generic Process Appropriate utilizati-
on: systemic therapy 
Percentage of incident cancer patients receiving systemic 
therapy post-operatively. 
Generic Process Appropriate utilizati-
on: RT 
Percentage of cancer cases receiving RT within 1 year of di-
agnosis. 
Waiting Times Waiting times: surge-
ry 
Median, 90th percentile surgical waiting times (date of pre-
operative consultation to date of surgery) among patients 
undergoing breast, colorectal, lung, and prostate cancer 
surgery in Ontario. 
Waiting Times Waiting times: 
systemic therapy 
Median, 90th percentile number of weeks from referral to 
start of systemic therapy for new patients. 
Waiting Times Waiting times: RT Median, 90th percentile number of weeks from referral to 
start of RT for new patients. 
(Generic Proc-
ess*) 
Patient satisfaction 
with access to care 
Oncology patient satisfaction survey results related to wait-
ing times and access to care. 
End-of-Life Palliative care utiliza-
tion 
Rates of palliative care utilization among cancer patients. 
Generic Process Pain management Patients’ self-reported pain. 
(Generic Proc-
ess*) 
Pain management Patients’ perception of pain management by providers. 
(Generic Proc-
ess*) 
Improve access 
to cancer ser-
vices and reduce 
waiting times 
Patient satisfaction 
overall 
Oncology patient satisfaction survey results related to pa-
tient journey overall. 
* Indicators referring to patient satisfaction are in the domain of outcome quality and therefore not included here. In 
terms of process quality it is necessary to incorporate patient satisfaction surveys related to various aspects of care 
into the care process in order to then be able to answer questions about patient satisfaction. 
Source: Greenberg (2005), table 3 
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CSQI (2011) 
Cancer System Quality Index Indicators CSQI, Ontario, Canada 
Category Indicator 
 
Quality Dimension 
Generic Process  Reporting of Cancer Stage at Diagnosis Effective, Accessible 
Generic Process  Multidisciplinary Cancer Conferences (MCC) Effective, Accessible 
Generic Process  Radiation Treatment Utilization Effective, Accessible 
Generic Process  Synoptic Pathology Reporting Effective, Accessible 
(Generic Process*)  Patient Experience with Outpatient Cancer Care Responsive 
Generic Process  Symptom Assessment Responsive 
Waiting Times  Wait Times from Surgery to Adjuvant Chemotherapy Integrated 
End-of-Life  End-of-Life Care 
o Percentage of cancer patients who were admitted to the ICU in 
the last two weeks of life 
o Percentage of cancer patients who visited the emergency depart-
ment up to two weeks before death 
o Percentage of cancer patients who died in acute care hospital 
o Median number of days in acute care for last 6 months of life for 
patients who died of cancer in Ontario 
Responsive 
 
End-of-Life  Chemotherapy in the Last Two Weeks of Life Efficient 
* Indicators referring to patient satisfaction are in the domain of outcome quality and therefore not included here. In 
terms of process quality it is necessary to incorporate patient satisfaction surveys related to various aspects of care 
into the care process in order to then be able to answer questions about patient satisfaction. 
Source: www.cqco.ca/cms/One.aspx?portalId=89621&pageId=89823 
NCASP (2011) 
National Clinical Audit Support Programme NCASP – Example Bowel Cancer Audit 
Category Indicator Reference 
Generic Proc-
ess 
Discussed at MDT meet-
ing 
 
NICE guidance and Peer Review recommendations are that 95 per cent to 
100 per cent of patients should be discussed at an MDT meeting 
Generic Proc-
ess 
Seen by clinical nurse 
specialist 
NICE guidance is that 100 per cent of patients should be seen by a specialist 
nurse. 
Source: NHS Information Centre (2011) 
 
AQUA (2011) 
Institute for Applied Quality Improvement and Research in Health Care AQUA: quality indicators breast 
cancer surgery 
Category QI Description 
Generic Process QI 9 Reporting to cancer registry 
Waiting Times QI 10 Time from diagnosis to surgery 
Source: AQUA (2011), page 6 
Method and indicator selection 
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NPK Monitor (2009) 
Netherlands National Cancer Control Programme NPK: quality indicators NPK 
Monitor 
Category Domain Quality measure 
 
Cancer Care 
Generic Pro-
cess* 
Stage at diagnosis 
Generic Process Compliance to guidelines 
Waiting Time 
 
Time from diagnosis to treatment 
*Documentation is aspect of process quality. 
Source: NPK Monitor: 
www.npknet.nl/share/files/205_107897/NPK%20monitorkaartje%20ENG%202009.pdf 
 
Vlayen (2011) 
Belgian Health Care Knowledge Center KCE Projects: Indicators relevant as 
generic if used in more than one type of cancer. 
Vlayen (2011) – Rectal cancer 
Category Domain Quality measure 
 
Generic pro-
cess 
General Quality 
indicators: pro-
cess 
Proportion of patients discussed at a MDT meeting 
Source: Vlayen (2011), appendix 3, table 16 
 
Vlayen (2011) – Breast cancer 
Category Domain Quality measure 
 
Generic Process Proportion of breast cancer women discussed at 
the MDT meeting 
Generic Process 
General Quality in-
dicators: processes 
Proportion of women with breast cancer who 
participate in clinical trials 
Generic Process (Adjuvant) treat-
ment 
Proportion of women with a breast cancer who 
are receiving intravenous chemotherapy for 
whom the planned chemotherapy regimen 
(which includes, at a minimum: drug[s] pre-
scribed, dose, and duration) is documented prior 
to the initiation, and at each administration of 
the treatment regimen 
Source: Vlayen (2011), appendix 3, table 16 
 
Generic indicators for process quality in oncological care 
18 LBI-HTA | 2012 
Vlayen (2011) – Testis cancer 
Category Domain Quality measure 
 
Generic Process Proportion of patients with testicular cancer dis-
cussed at the MDT meeting 
Generic Process 
General quality in-
dicators: 
processes Proportion of patients with relapsing testicular 
cancer after curative treatment that are in-
cluded in a clinical trial 
 
Source: Vlayen (2011), appendix 3, tabelle 16 
 
NIP (2011) 
Danish National Indicator Program NIP – Lung Cancer – Indicators and 
Standards: Waiting times are lung cancer specific here but could 
be adapted to other cancers. 
 
Category Type Indicator 
Domain 
Indicator 
Waiting 
Time 
Proportion of patients, for whom the diagnostic 
package is completed within 28 days of referral 
Waiting 
Time 
Proportion of patients having surgery within 14 days 
after acceptance of the further treatment course 
(i.e. referral to surgery) 
Waiting 
Time 
Proportion of patients having surgery within 42 days 
of referral to the diagnostic package 
Waiting 
Time 
Proportion of patients who initiate chemotherapy 
within 14 days of acceptance of the further treat-
ment course (i.e. referral to chemotherapy) 
Waiting 
Time 
Proportion of patients who initiate chemotherapy 
within 42 days after referral to the diagnostic pack-
age 
Waiting 
Time 
Proportion of patients who initiate radiation therapy 
within 14 days after acceptance of the further 
treatment course (i.e. referral to radiation therapy) 
Waiting 
Time 
Process Diagnosing 
and treat-
ment time 
Proportion of patients who initiate radiation therapy 
within 42 days of referral to the diagnostic package 
Source: Danish National Indicator Program: 
www.nip.dk/files/Subsites/NIP/Om%20NIP/About%20NIP/Lung%20Cancer.pdf 
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3 Results of indicator selection 
The generic process indicators found above in the pool of 17 indicator sets 
are presented grouped in the following domains defined by the authors: 
1. Patient communication 
2. Waiting time 
3. Documentation 
4. Reporting 
5. Guideline adherence 
6. Clinical trial participation 
7. Multidisciplinarity 
8. Pain management 
9. Dyspnea management 
10. Depression/ Emotional well-being 
11. General processes 
12. Information technology (IT) 
13. Cancer research funding 
14. Innovation 
15. Radiation therapy quality assurance 
16. Advance care planning (ACP) 
17. End-of-life 
3.1 Overview of generic indicators 
Five of the 17 indicator sets did not contain any generic process indicators. 
Table 2 below gives an overview of all generic process indicators found in 
the remaining pool of 12 indicator sets. 
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Table 2: Overview generic process indicators found in pool of indicator sets 
BOLD if found in more than one indicator set 
 
Explanation of information contained in field “Indicator” with an example: 
Indicator Documentation: Staging documented 
1 within one month of first office visit 
3 at diagnosis 
 
This indicator was found in four indicator sets (X X X X), 
first indicator set (X X X X) additionally specifies “within one month of first office visit”, 
third indicator set (X X X X)additionally specifies “at diagnosis” 
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Domain Subgroup Indicator 1 2 3.
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3
.
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3
.
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3
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3
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3
.
8 
3
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0 
1
1
.
1 
1
1
.
2 
1
1
.
3 
1
2 
Patient 
communication 
 Patient satisfaction surveys related to various aspects of care con-
ducted 
             x x        
Patient 
communication 
 Signed patient consent for chemotherapy            x           
Patient 
communication 
 Chemotherapy treatment summary provided to patient within 3 
months of chemotherapy end 
           x           
Patient 
communication 
 Infertility risks discussed prior to chemotherapy with patients of 
reproductive age (Symptom/Toxicity Management – Chemother-
apy-Related) 
           x           
Patient 
communication 
 Fertility preservation options discussed or referral to specialist 
(Symptom/Toxicity Management – Chemotherapy-Related) 
           x           
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Domain Subgroup Indicator 1 2 3.
1 
3
.
2 
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.
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.
8 
3
.
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1
.
1 
1
1
.
2 
1
1
.
3 
1
2 
Patient 
communication 
 Symptom Assessement 
Percentage of cancer patients who were screened at least once per 
month for symptom severity 
              x        
Waiting Time  From diagnosis to treatment                  x     
Waiting Time  From referral to completion of diagnostic package                      x 
Waiting Time  From referral to diagnostic package to surgery                      x 
Waiting Time  From diagnosis to surgery                 x      
Waiting Time  From referral to surgery                      x 
Waiting Time  From initial consultation with surgeon to surgery x             x         
Waiting Time  From referral to diagnostic package to chemotherapy                      x 
Waiting Time  From referral to chemotherapy              x        x 
Waiting Time  From surgery to adjuvant chemotherapy              x         
Waiting Time  From referral to diagnostic package to radiation therapy                      x 
Waiting Time  From referral to radiation therapy              x        x 
Documentation  Pathology report 
1 confirming malignancy 
2 (QI) 
           x x          
Documentation Staging Staging documented 
1 within one month of first office visit 
3 at diagnosis 
           x x  x   x     
Documentation Stage capture rate Proportion of incident cancer cases in which a cancer stage was 
identified. 
             x         
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Domain Subgroup Indicator 1 2 3.
1 
3
.
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.
1 
1
1
.
2 
1
1
.
3 
1
2 
Documentation Care Planning Plan of care for pain documented 
1 for moderate/severe pain 
2 Medical Oncology and Radioation Oncology 
           x x          
Documentation Care Planning Chemotherapy intent (curative vs. palliative) documented            x           
Documentation Care Planning Documented plan for chemotherapy 
1 including doses, route, and time intervals 
3 at a minimum: drug[s] prescribed, dose, and duration) is docu-
mented prior to the initiation, and at each administration of the 
treatment regimen 
           x x       x   
Documentation Patient consent Chemotherapy intent discussion with patient documented            x           
Documentation Patient consent Patient consent documented in practitioner note            x           
Documentation  Number of chemotherapy cycles documented            x           
Documentation  Chemotherapy treatment summary 
1 completed within 3 months of chemotherapy end 
2 Medical Oncology (QI) 
           x x          
Documentation Symptom/Toxicity 
Management – Che-
motherapy-Related 
Baseline iron stores documented within 90 days prior to admini-
stration of ESAs 
           x           
Documentation Symptom/Toxicity 
Management – Che-
motherapy-Related 
Hemoglobin < 10g/dL documented within 2 weeks prior to ad-
ministration of ESAs 
           x           
Reporting  Percentage of cases reported to cancer registry                 x      
Reporting  Percentage of hospitals submitting all required data on cancer di-
agnosis and treatment on time/ Percentage of data by cancer ser-
vice modality that is submitted 
             x         
Reporting  Synoptic Pathology Reporting 
1 Percentage of pathology reports submitted that are reported 
synoptically 
             x x        
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Domain Subgroup Indicator 1 2 3.
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1
1
.
3 
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Guideline adherence  Compliance to guidelines              x    x     
Clinical trial partici-
pation 
 Participation in Clinical Trials 
1 Number of patients recruited to clinical trials for chemotherapy, 
radiotherapy, and interventions studies by hospital. 
             x      x x 
 
 
Multidisciplinarity  Patient discussed at multidisciplinary forum 
1 Multidisciplinary Cancer Conferences 
2 Multi Disciplinary Team Meeting 
              x x   x x x  
Multidisciplinarity  Patient seen by clinical nurse specialist                x       
Multidisciplinarity Communication Treatment summary 
1 chemotherapy treatment summary provided or communicated 
to practitioner(s) within 3 months of chemotherapy end 
2 radiation oncology and medical oncology (QI) 
           x x          
Pain management Assessment Pain Assessment 
1 regular 
2 routine 
3 routine inpatient 
4 pain assessed by second office visit 
  x     x  x  x           
Pain management Assessment Pain Assessment regular in ICU         x              
Pain management Assessment Pain intensity quantified 
1 routine with a numeric scale 
2 by second office visit 
3 medical oncology and radiation oncology 
4 patients’ self-reported pain 
         x  x x x         
Pain management Assessment Effectiveness of narcotic assessed on visit following prescription            x           
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Domain Subgroup Indicator 1 2 3.
1 
3
.
2 
3
.
3 
3
.
4 
3
.
5 
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.
6 
3
.
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3
.
8 
3
.
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4 5 6 7 8 9 1
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1
1
.
1 
1
1
.
2 
1
1
.
3 
1
2 
Pain management Constipation Constipation assessed at time of narcotic prescription or following 
visit 
           x           
Pain management Constipation Regular prophylaxis of opiate-induced constipation          x             
Pain management Treatment Pain Treatment 
1 responsive 
2 effective for painful bony metastasis 
3 timely of inpatient pain 
4 patients’ perception of pain management by providers 
  x   x    x    x         
Pain management Treatment Effective pain treatment 
in ICU 
        x              
Dyspnea 
management 
Assessment Regular dyspnea assessment          x             
Dyspnea 
management 
Treatment Dyspnea treatment 
1 dyspnea caused by hypoxia 
2 timely of inpatient 
  x       x             
Depression/ Emo-
tional well-being 
Assessment Assessment emotional well-being 
1 Regular assessment for psychological well-being 
2 Patient emotional well-being assessed by the second office visit 
         x  x           
Depression/ Emo-
tional well-being 
Treatment Action taken to address problems with emotional well-being by 
the second office visit 
           x           
Depression Assessment/ Treat-
ment 
Regular assessment or treatment of depression in newly diag-
nosed cancer 
   x                   
Depression Assessment/ Treat-
ment 
Routine assessment or treatment of depression in symptomatic 
patients 
   x                   
General processes Appropriate utilizati-
on: systemic therapy 
Percentage of incident cancer patients receiving systemic therapy 
post-operatively. 
             x         
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Domain Subgroup Indicator 1 2 3.
1 
3
.
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General processes Appropriate utilizati-
on radioation treat-
ment 
Radiation Treatment Utilization 
1 percentage of cancer cases receiving radiation therapy within 
one year of diagnosis 
             x x        
General processes Symptom/Toxicity 
Management – Che-
motherapy-Related 
Serotonin antagonist prescribed with moderate/high emetic risk 
chemotherapy 
           x           
General processes Symptom/Toxicity 
Management – Che-
motherapy-Related 
Corticosteroids and serotonin antagonist prescribed with moder-
ate/high emetic risk chemotherapy 
           x           
General processes Symptom/Toxicity 
Management – Che-
motherapy-Related 
Aprepitant prescribed with high emetic risk chemotherapy            x           
Information Tech-
nology 
Integrated IT systems Percentage of hospitals that meet volume cut-off for cancer ser-
vices that have single view of patient results available in the hos-
pital to appropriate providers that include diagnostic, procedural, 
systemic, and radiation therapy information 
             x         
Information Tech-
nology 
Automatization Percentage of medical oncologists using “Computerized Physician 
Order Entry” systems. 
             x         
Cancer Research 
Funding 
 Percentage of Integrated Cancer Programs’ annual budgets de-
voted to cancer research funding 
             x         
Innovation  Hospitals’ self-reported environments for innovation (question-
naire) 
             x         
Radiation therapy 
quality assurance 
 Percentage of RT facilities in compliance with “Healing Arts Radia-
tion Protection” guidelines 
             x         
Advance Care Plan-
ning ACP 
 Advance care planning             x          
ACP  Timely and effective discharge planning          x             
ACP Surrogate Regular identification of a surrogate in the outpatient setting    x                   
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Domain Subgroup Indicator 1 2 3.
1 
3
.
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.
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2 
ACP Surrogate Regular identification of a surrogate among hospital admissions 
with impaired cognition 
   x                   
ACP Surrogate Regular identification of a surrogate in the ICU         x              
ACP Preferences 
Assessment 
Regular assessment of preferences among inpatients with demen-
tia 
   x                   
ACP Preferences 
Assessment 
Regular assessment of preferences in hospice           x            
ACP Preferences 
Assessment 
Regular assessment of preferences in an ICU 
2 specific resuscitation preferences 
   x     x              
ACP Preferences 
Assessment 
Regular assessment of advance directives for ICU patients         x              
ACP Preferences 
Documentation 
Documentation of care preferences across venues    x                   
ACP Preferences 
Documentation 
Documentation specific life sustaining preferences    x                   
ACP Preferences 
Follow-up 
Consistency of preferences with use of ventilator support    x                   
ACP Preferences 
Follow-up 
Care consistency with documented care preferences    x         x          
ACP Communications Regular clinician-patient-family communication in the ICU         x              
ACP Communications Regular family meetings among hospitalized patients          x             
ACP  Regular patient participation in decisions to limit treatment    x                   
End-of-life  Death in acute-care bed 
3 site of death 
x x     x        x        
End-of-life  More than one hospitalization in the last 30 days of life  x                     
End-of-life  Median number of days in acute care for last 6 months of life for 
patients who died of cancer 
              x        
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Domain Subgroup Indicator 1 2 3.
1 
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.
3 
1
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End-of-life 
 
 
 
 
 Emergency department visit 
1 in the last two weeks of life 
2 more than one ER visit in the last 30 days of life 
3 ER visit in the last month of life 
4 ER visit in the last month of life 
5 in the last two weeks of life 
x x   x  x        x        
End-of-life  Intensive care unit admission 
1 in the last 30 days of life 
2 in the last 14 days of life 
 x             x        
End-of-life  Chemotherapy in the last two weeks of life x x     x     x   x        
End-of-life  Home care visit in the last 6 months of life x                      
End-of-life  Physician house calls in the last two weeks of life x                      
End-of-life Hospice/ Palliative 
care 
Hospice enrolment 
1 not admitted to hospice (inverse) 
2 admission to hospice (equivalent to: Death in acute-care bed) 
3 hospice or palliative care referral 
4 rates of palliative care utilization 
 x     x     x  x         
End-of-life Hospice Admitted to hospice for less than 
1 three days 
2 seven days 
 x          x           
End-of-life Hospice For patients not referred, hospice or palliative care discussed 
within the last 2 months of life 
           x           
End-of-life Hospice Family evaluation of hospice care 
2 Survey of caregivers after death 
 x         x            
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Domain Subgroup Indicator 1 2 3.
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End-of-life Pain 
Assessment 
Routine pain assessment in expected dying    x                   
End-of-life Pain 
Assessment 
Pain assessed on either of the last two visits before death            x           
End-of-life Pain 
Assessment 
Pain intensity quantified on either of the last two visits before 
death 
           x           
End-of-life Pain 
Documentation 
lan of care for moderate/severe pain documented on either of the 
last two visits before death 
           x           
End-of-life Pain 
Treatment 
Comfortable dying: pain  x                     
End-of-life Pain 
Treatment 
Timely treatment of pain in hospice           x            
End-of-life Dyspnea 
Assessment 
Dyspnea assessed on either of the last two visits before death 
2 Dyspnea screening 
           x x          
End-of-life Dyspnea 
Treatment 
Effective treatment in expected dying    x                   
End-of-life Dyspnea 
Treatment 
Regular treatment and follow-up in expected dying    x                   
End-of-life Dyspnea 
Treatment 
Dyspnea addressed on either of the last two visits before death 
2 Dyspnea management 
           x x
 
         
End-of-life Depression/ Spiritual 
well-being 
Assessment 
Regular spiritual assessment in expected dying 
   x                   
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31 generic process indicators were found in more than one indicator set.  
 Waiting time (4) 
 Documentation (5) 
 Reporting (1) 
 Guideline adherence (1) 
 Clinical trial participation (1) 
 Multidisciplinarity (2) 
 Pain management (3) 
 Dyspnea management (1) 
 Depression/ Emotional well-being (1) 
 General processes (1) 
 Advance care planning (2) 
 End-of-life (9) 
These are presented in table 3 below. 
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Table 3: Generic process indicators found at least twice in pool of indicator sets 
No. Domain 
 
Subgroup Indicator Details/ Source 
1 Patient 
communication 
 Patient satisfaction surveys related to various aspects of 
care conducted 
In order to answer questions about patient satisfaction with various aspects of care 
(Greenberg 2005: coordination of care, access to care, pain management, overall, CSQI 
2011: experience with outpatient cancer care) the respective surveys need to be incorpo-
rated in the care process. 
2 Waiting Time  From initial consultation with surgeon to surgery Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92546  
3 Waiting Time  From referral to chemotherapy Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92651  
4 Waiting Time  From referral to radiation therapy Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92598  
5 Documentation  Pathology report American Medical Association and American Society of Clinical Oncology 
http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/oncology-worksheets.pdf  
Measure #10 
6 Documentation Staging Staging documented Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92520  
7 Documentation Care Planning Plan of care for pain documented American Medical Association and American Society of Clinical Oncology 
http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/oncology-worksheets.pdf  
Measure #9 
8 Documentation Care Planning Documented plan for chemotherapy American Medical Association and American Society of Clinical Oncology 
http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/oncology-worksheets.pdf 
Measure #6 
9 Documentation  Chemotherapy treatment summary American Medical Association and American Society of Clinical Oncology 
http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/oncology-worksheets.pdf 
Measure #5 
10 Reporting  Synoptic Pathology Reporting Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92533  
11 Guideline 
adherence 
 Compliance to guidelines NPK Monitor 2009 
http://www.npknet.nl/2210-p-1908  
12 Clinical trial par-
ticipation 
 Participation in Clinical Trials Greenberg (2005), table 3 
13 Multidisciplinarity  Patient discussed at multidisciplinary forum Most far reaching concept: Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92559  
14 Multidisciplinarity Communication Treatment summary American Medical Association and American Society of Clinical Oncology 
http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/oncology-worksheets.pdf 
Measure #5 and # 6 
15 Pain 
management 
Assessment Pain Assessment Georgia Cancer Coalition 
Lorenz (2006): appendix F1 
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No. Domain 
 
Subgroup Indicator Details/ Source 
16 Pain 
management 
Assessment Pain intensity quantified University Health Consortium 
Lorenz (2006): appendix F1 
17 Pain 
management 
Treatment Pain Treatment RAND 
Lorenz (2006): appendix F1 
18 Dyspnea 
management 
Treatment Dyspnea treatment University Health Consortium 
Lorenz (2006): appendix F2 
19 Depression/ Emo-
tional well-being 
Assessment Assessment emotional well-being University Health Consortium 
Lorenz (2006): appendix F3 
20 General 
Processes 
Appropriate utilization ra-
dioation treatment 
Radiation Treatment Utilization Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92612  
21 Advanced Care 
Planning ACP 
Preferences 
Assessment 
Regular assessment of preferences in an ICU Assessing the Care Of Vulnerable Elders ACOVE 
Lorenz (2006): appendix F4 
22 ACP Preferences 
Follow-up 
Care consistency with documented care preferences Assessing the Care Of Vulnerable Elders ACOVE 
Lorenz (2006): appendix F4 
23 End-of-life  Death in acute-care bed Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92397  
24 End-of-life  Emergency department visit Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92397 
25 End-of-life  Intensive care unit admission Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92397 
26 End-of-life  Chemotherapy in the last two weeks of life Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId=89621&pageId=92397 
27 End-of-life Hospice/ Palliative care Hospice enrolment National Quality Forum 
NQF (2009a), A-14 
28 End-of-life Hospice Admitted to hospice for less than National Quality Forum 
NQF (2009a), A-14 
29 End-of-life Hospice Family evaluation of hospice care National Quality Forum 
NQF (2009a), A-9 
Details on family evaluation survey: NQF (2009a), figure A-1, table A-1 
30 End-of-life Dyspnea 
Assessment 
Dyspnea assessed on either of the last two visits before 
death 
American Medical Association and American Society of Clinical Oncology 
http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/palliative-care.pdf  
Measure #2 
31 End-of-life Dyspnea 
Treatment 
Dyspnea addressed on either of the last two visits before 
death 
American Medical Association and American Society of Clinical Oncology 
http://www.ama-assn.org/ama1/pub/upload/mm/pcpi/palliative-care.pdf  
Measure #2 
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3.2 Detailed description of generic process indicators 
Detailed information about the 31 generic process indicators found in more than one of the pool indica-
tor sets is presented below: 
 
No. Domain Subgroup Indicator Details/ Source 
1 Patient 
communication 
 Patient satisfaction surveys re-
lated to various aspects of care 
conducted 
In order to answer questions about patient 
satisfaction with various aspects of care 
(Greenberg 2005: coordination of care, ac-
cess to care, pain management, overall, 
CSQI 2011: experience with outpatient can-
cer care) the respective surveys need to be 
incorporated in the care process. 
 
 
No. Domain Subgroup Indicator Details/ Source 
2 Waiting Time  From initial consultation with 
surgeon to surgery 
Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId
=89621&pageId=92546  
 
 
Wait time for cancer surgery 
Definition 
Percent of cancer surgery patients treated within 14, 28 and 84 days access target for priority 2,3 
and 4 cases, respectively 
Calculation 
Total # of patients treated within their respective 
priority targets 
 
Total # of cancer surgery patients 
X 100 
=  
 
Percentage of treatment 
within target 
 
Analysis 
 Provincial trend from January 2009 to December 2010, by Priority Access Target Disease 
Site and LHIN  
Considerations 
 The percent of cancer surgery patients treated within 14, 28 and 84 days is weighted 
based on volume by priority.  
Technical Speci-
fications 
 Wait time (in days) for cancer surgery is calculated as:  
 Surgery Operation Date – Decision to Treat Date – Patient Unavailable Days 
 Based on closed cases, with operation dates within date range, submitted by hospitals 
through the Wait Time Information System (WTIS). 
 Procedures classified as "NA" are currently included.  
 If unavailable days fall outside the decision to treat date up to procedure date, unavail-
able days are not deducted from patients’ wait days. These are considered data entry er-
rors. 
Exclusions: 
 Individuals <18 years old 
 Procedures that are no longer required for submission 
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 Skin – carcinoma, skin – melanoma, and lymphomas 
 Priority 1 procedures 
 Diagnostic, palliative, and reconstructive cancer procedures 
 Non cancer diagnosis 
 Wait list entries identified by hospitals as data entry errors 
Numerator 
 Total # of cancer surgery patients treated within their respective priority access targets; 
14, 28 and 84 days for priority 2,3 and 4 cases, respectively  
Denominator 
 Total # of cancer surgery patients after exclusion 
Data Sources 
 Wait Time Information System, Cancer Care Ontario 
Data Availability 
& Limitations 
 Calculated for the period between January 2009 and December 2010  
 Guidelines are implemented to ensure the facilities submit their data through WTIS in 
close to real time at source. A 2-business-day rule has been put in place for opening a wait 
list entry in the system when the decision for treatment is made, and closing the entry af-
ter the procedure is performed. This rule is established to ensure compliance with timely 
data submissions.  
 It is possible to allow for an audit trail back to the original source of data in the physi-
cian’s office or the hospital scheduling system 
 
 
No. Domain Subgroup Indicator Details/ Source 
3 Waiting Time  From referral to chemotherapy Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId
=89621&pageId=92651  
 
Wait time systemic therapy “consult to treatment” 
 
Definition Percentage of patients that are seen within the consult to treatment wait time target for systemic therapy  
Calculation 
Total Number of Patients within Ready to treat to 
treat wait time target 
 
Total Number of Valid Cases 
X 100 
=  
Percent of patients seen 
within target 
 
Analysis 
 January to December 2009, 2010, by Regional Cancer Centre and Disease Site 
Considerations 
 The consult to treatment activity presented in this report is limited to treatment activ-
ity provided within the Regional Cancer Centres which covers about 65% of the provin-
cial activity.  
Technical Specifica-
tions 
 Systemic Consult to Treatment patients are those patients with both a valid Consult and 
Treatment Date receiving treatment at the Regional Cancer Centre. 
 Only new treatments for a particular disease site are included 
Exclusions: 
 Diagnosis site not between ‘C00’ and ‘D49’ 
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Definition Percentage of patients that are seen within the consult to treatment wait time target for systemic therapy  
 Consult date is null  Consult date is greater than Treatment date 
 Program Code is Radiation and Treatment is non-IV chemotherapy 
Numerator 
 Total number of patients within ready to treat to treatment wait time of 1, 7 and 14 
days 
Denominator 
 Total number of cases with a valid Treatment Date during the reporting time period 
Data Sources 
 Activity Level Reporting, Cancer Care Ontario 
Data Availability & 
Limitations 
 Data for the 2 intervals referral to consult and ready to treat to treatment are available 
only from April 2007 onwards. 
Only new systemic patients are included (excludes re-treats)  
 
 
No. Domain Subgroup Indicator Details/ Source 
4 Waiting Time  From referral to radiation ther-
apy 
Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portalId
=89621&pageId=92598  
 
 
Wait Times for Radiation Treatment “Ready to Treat to Treatment” 
Definition Percentage of patients that are seen within the ready to treat to treatment wait time target  
Calculation 
Total Number of Patients within Ready to treat to 
treat wait time target 
 
Total Number of Valid Cases 
X 100 
=  
Percent of patients seen 
within target 
 
Analysis 
 January to December 2009, 2010, by Regional Cancer Centre and Disease Site 
Considerations 
 The ready to treat to treatment activity presented in this report is limited to treatment 
activity provided within the Regional Cancer Centres.  
Technical Specifica-
tions 
 Radiation Ready to Treat to Treatment patients are those patients with both a valid 
Ready to Treat and Treatment Date receiving treatment at the cancer centre. 
 Only new treatments for a particular disease site are included 
Exclusions: 
 Diagnosis site not between ‘C00’ and ‘D49’  Treatment date is null  Ready to Treat date is null 
 Ready to Treat date is greater than Treatment date 
Numerator 
 Total number of patients within ready to treat to treatment wait time of 1, 7 and 14 
days 
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Definition Percentage of patients that are seen within the ready to treat to treatment wait time target  
Denominator 
 Total number of cases with a valid Treatment Date during the reporting time period 
Data Sources 
 Activity Level Reporting, Cancer Care Ontario 
Data Availability & 
Limitations 
 Data for the 2 intervals referral to consult and ready to treat to treatment are available 
only from April 2007 onwards. 
Only new radiation patients are included (excludes re-treats)  
 
 
No. Domain Subgroup Indicator Details/ Source 
5 Documenta-
tion 
 Pathology report American Medical Association and 
American Society of Clinical Oncology 
http://www.ama-
assn.org/ama1/pub/upload/mm/pcpi/onco
logy-worksheets.pdf  
Measure #10 
 
Pathology Report 
This measure is appropriate as a Quality Improvement measure only. 
 
Clinical Performance Measure  
Numerator: Patients with a pathology report in the medical record that confirms malignancy prior to the initiation 
of therapy  
Denominator: All patients with a diagnosis of cancer receiving chemotherapy or radiation therapy  
Denominator Exceptions:  
Documentation of medical reason(s) for not having a pathology report in the medical record that confirms malig-
nancy prior to the initiation of therapy (eg, palliative treatment for metastatic illness)  
Measure: Percentage of patients with a diagnosis of cancer receiving chemotherapy or radiation therapy with a pa-
thology report in the medical record that confirms malignancy prior to the initiation of therapy  
The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and 
represent the evidence base for the measure:  
The cognitive process of treatment planning requires the radiation oncologist to have knowledge of the natural his-
tory of the tumor to be treated and to determine the tumor site, its extent, and its relationship with adjacent nor-
mal tissues. This process is based on consideration of the history, physical examination, endoscopy, diagnostic imag-
ing, findings at surgery, and histology (ACR)  
A practice must demonstrate that it performs an adequate clinical evaluation by taking a patient history, perform-
ing a physical examination, reviewing pertinent diagnostic studies and reports, determining the extent of the tumor 
for staging purposes, and communicating with the referring physician and certain other physicians involved in the 
patient’s care. (ACRO)  
Rationale for the measure:  
The extent of the tumor must be determined and recorded for staging; this will facilitate treatment decisions, de-
termine prognosis, and allow a comparison of treatment results.  
Data capture and calculations:  
Calculation for Performance  
For performance purposes, this measure is calculated by creating a fraction with the following components: Nu-
merator, Denominator, and Denominator Exclusions.  
Performance Numerator (A) Includes:  
 Patients with a pathology report in the medical record that confirms malignancy prior to the initiation of 
therapy  
 
Performance Denominator (PD) Includes:  
 All patients with a diagnosis of cancer receiving chemotherapy or radiation therapy  
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Performance Denominator Exceptions (C) Include:  
 Documentation of a medical reason(s) for not having a pathology report in the medical record, confirming 
malignancy prior to the initiation of therapy (eg, palliative treatment for metastatic illness) 
 
Performance Calculation 
A (# of patients meeting numerator criteria) divided by 
PD (# of patients in denominator) – C (# of patients with valid denominator exclusions)  
 
 
Components for this measure are defined as:  
A  
# of patients with a pathology report in the medical record that confirms malignancy prior to the initiation of ther-
apy  
PD  
# of patients with a diagnosis of cancer receiving chemotherapy or radiation therapy  
C  
# of patients with a documented medical reason(s) for not having a pathology report in the medical record, con-
firming malignancy prior to the initiation of therapy (eg, palliative treatment for metastatic illness)  
Calculation for Reporting  
For reporting purposes, this measure is calculated by creating a fraction with the following components: Reporting 
Numerator and Reporting Denominator  
Reporting Numerator includes each of the following instances:  
A. Patients who have a pathology report in the medical record that confirms malignancy prior to the initiation of 
therapy  
C. Patients with a documented medical reason(s) for not having a pathology report in the medical record, confirm-
ing malignancy prior to the initiation of therapy (eg, palliative treatment for metastatic illness)  
D. Patients who do not have a pathology report in the medical record that confirms malignancy prior to the initia-
tion of therapy 
 
Reporting Calculation  
A (# of patients meeting numerator criteria) + C (# of patients with valid exclusions) + D (# of patients not meet-
ing numerator criteria) divided by 
RD (# of patients in denominator) 
 
Reporting Denominator (RD) Includes:  
All patients with a diagnosis of cancer receiving chemotherapy  
A  
# of patients with a pathology report in the medical record that confirms malignancy prior to the initiation of ther-
apy  
C  
# of patients who do not have a pathology report in the medical record that confirms malignancy prior to the initia-
tion of therapy and there is a documented medical reason for not doing so  
D  
# of patients who do not have a pathology report in the medical record that confirms malignancy prior to the initia-
tion of therapy  
RD  
# of patients with a diagnosis of cancer receiving chemotherapy or radiation therapy  
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No. Domain Subgroup Indicator Details/ Source 
6 Documentation Staging Staging documented Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portal
Id=89621&pageId=92520  
 
 
Reporting of Cancer Stage at Diagnosis (Population-based stage capture rate) 
Definition 
The population-based measure reports the percentage of all eligible new cancer cases in Ontario for 
which a valid stage at diagnosis is derived from information in the Ontario Cancer Registry (OCR) and 
the CS database.  
Calculation 
Reportable incident cases in Ontario Cancer Registry where a 
valid stage at diagnosis is available 
 
Reportable incident cases in Ontario Cancer Registry which are 
TNM stageable 
X 100 
=  
Population Stage 
Rate 
 
Analysis 
 For Jan. 2006 – Dec 2009 
 % of reportable incident cases in OCR with valid stage by fiscal year, LHIN, by top four dis-
ease sites (Breast, Colorectal, Lung, Prostate) 
Considerations 
 The AJCC Collaborative Staging (CS) coding system is used by CCO CS analysts to collect the 
base data elements from cancer patient hospital health records (i.e., cancer pathology re-
port, CT/MRI or other radiology reports, operative note, etc) in 85 hospitals across On-
tario. CS data collection is semi-automated with electronic data capture from CCO’s ePath 
data holdings and OCRIS. The CS minimum data set can derive AJCC TNM staging values 
and includes additional prognostic information such as PSA test results for prostate cancer 
and ER/PR results for breast cancer  
 This indicator does not assess the accuracy of the staging information. It is a measure of 
the completeness in reporting  
 The calculation integrates two sources of stage data: AJCC TNM staging which is reported 
to CCO by Ontario’s 14 Cancer Centres and the Collaborative Staging (CS) data collection 
system where trained CCO abstractors collect the base data elements from hospital health 
records (i.e., cancer pathology report, CT/MRI or other radiology reports, operative note, 
etc) via remote access to charts in 71 other Ontario hospitals. Starting in March 2010, CS 
data collection was also initiated in RCCs, to obtain staging for the 2007, 2008 and 2009 
diagnosis years for cases where TNM stage was not submitted to CCO 
 In-situ cases are not included 
 Currently the CS data collection system in Ontario is limited to the top four disease sites; 
expansion to other sites will begin in 2011/12 
 CS is a new data collection system for staging of cancer based on the TNM categories and 
stage groupings, Summary Stage, and the SEER Extent of Disease coding structure. The de-
velopment of the Collaborative Staging coding system was sponsored by the American 
Joint Committee on Cancer (AJCC) in collaboration with the National Cancer Institute Sur-
veillance, Epidemiology and End Results Program (NCI-SEER); Centers for Disease Control 
and Prevention National Program of Cancer Registries (CDC/NPCR); National Cancer Regis-
trars Association (NCRA); North American Association of Central Cancer Registries 
(NAACCR); and American College of Surgeons (ACOS) Commission on Cancer 
(CoC). Collaborative Staging has been endorsed by all Canadian provinces/territories (in-
cluding Ontario) and US state registries as the pan-American standard for cancer staging 
data collection. 
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Technical Speci-
fications 
 Eligible cases include all cancers identifiable in OCR except those cancers for which TNM 
staging is not appropriate  
 For cases with multiple different valid stage values (due to multiple visits for Cancer Cen-
tres or staging using both TNM and CS systems), the resolved best stage is derived based on 
a specified algorithm  
 Inclusion of “Unknown” as a valid stage group, according to the AJCC Staging Guidelines.  
Exclusions: 
 Pediatric cases (those patients who are <18 years of age) 
 Non-melanoma skin  
 CCO Diagnosis grouping with primary unknown 
Numerator 
 Total number of reportable incident cases in OCR which a valid stage at diagnosis is avail-
able  
Denominator 
 Total number of reportable registered cases in OCR for which TNM staging is applicable 
and exclusion criteria are applied.  
Data Sources 
 Ontario Cancer Registry, Cancer Care Ontario 
 Activity Level Reporting, Cancer Care Ontario  
 Collaborative Staging Database, Cancer Care Ontario 
Data Availability 
& Limitations 
 The availability of population-based stage information relies on the timeliness of CIHI da-
tabase and Ontario Cancer Registry case resolution process. Usually it takes up to one and 
half years after diagnosis to ensure all cancer cases for a given year are identified; 
 Currently TNM stage data from RCC are available from April 2005 forward and CS data for 
top four disease sites are available from January 2007 forward;  
 Recent studies conducted to assess the timeliness, validity and reliability of stage data Col-
laborative Staging Data Quality Report for 2007 and 2008 found that these data are of 
high quality;  
 In 2010/11, starting with the 2010 diagnosis year, the CS data collection system will be used 
exclusively for the four most common cancers, TNM will continue to be collected by RCCs 
for other sites, until full CS implementation starting with the 2012 diagnosis year.  
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No. Domain Subgroup Indicator Details/ Source 
7 Documentation Care 
Planning 
Plan of care for pain docu-
mented 
American Medical Association and 
American Society of Clinical Oncology 
http://www.ama-
assn.org/ama1/pub/upload/mm/pcpi/onco
logy-worksheets.pdf  
Measure #9 
 
Plan of Care for Pain-Medical Oncology and Radiation Oncology  
This measure may be used as an Accountability measure.  
 
Clinical Performance Measure  
Numerator: Patient visits that included a documented plan of care* to address pain  
Numerator Instructions: *A documented plan of care may include: use of opioids, nonopioid analgesics, psychologi-
cal support, patient and/or family education, referral to a pain clinic, or reassessment of pain at an appropriate time 
interval.  
Denominator: All visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy 
or radiation therapy who report having pain  
Denominator Exceptions: None  
Measure: Percentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemo-
therapy or radiation therapy who report having pain with a documented plan of care to address pain  
The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and 
represent the evidence base for the measure:  
All patients with cancer should be screened during the initial evaluation, at regular intervals, and whenever new 
therapy is initiated. The standard means for determining how much pain a patient is experiencing relies on a pa-
tient's self-report. Severity should be quantified using a 0-10 numerical rating scale, a categorical scale, or the picto-
rial scale (Wong-Baker Faces Pain Rating Scale). Faces can be used with patients who have difficulty with the above 
scales, eg, children, the elderly, and patients with language or cultural differences or other communication barriers 
(Category 2A). (NCCN9)  
Pain intensity must be quantified, as the algorithm bases therapeutic decisions on a numerical value assigned to the 
severity of pain. Opioid nai¨ve patients experiencing severe or increasing pain should receive rapid escalating doses of 
short-acting opioids, a bowel regimen, and Nonopioid analgesics as indicated. Psychosocial support is needed to en-
sure that patients encountering common barriers to appropriate pain control (eg, fear of addiction or side effects, 
inability to purchase opioids) or needing additional assistance (eg, depression, rapidly declining functional status) 
receive appropriate aid. Although pain intensity ratings will be obtained frequently to judge opioid dose increases, a 
formal reassessment is mandated in 24 hours for severe pain (Category 2A). (NCCN9)  
For patients whose pain is less than 7 at presentation, the pathways are similar. The main differences include the op-
tion to perform the formal pain intensity reassessment less frequently (24-48 hours) and to consider beginning with 
slower titration of short-acting opioids for patients with moderate pain intensity rating 4-6 or with NSAID or 
acetaminophen if the patient has mild pain intensity rating from 1 to 0 and is opioid and NSAID-nai¨ve (Category 
2A). (NCCN9)  
Regular, ongoing assessment of pain, nonpain symptoms (including but not limited to shortness of breath, nausea, 
fatigue and weakness, anorexia, insomnia, anxiety, depression, confusion and constipation), treatment side effects 
and functional capacities are documented. Validated instruments, where available, should be used. (NCP12)  
All patients should be routinely screened for pain, and when it is present, pain intensity should be recorded in highly 
visible ways that facilitate regular review by health care providers. A standard for pain assessment and documenta-
tion should be established in each setting to ensure that pain is recognized, documented, and treated promptly. 
(APS13)  
Rationale for the measure:  
Inadequate cancer pain management is widely prevalent, harmful to the patient, and costly. There are no denomi-
nator exclusions for this measure.  
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Data capture and calculations:  
Calculation for Performance  
For performance purposes, this measure is calculated by creating a fraction with the following components: Nu-
merator and Denominator.  
Performance Numerator (A) Includes:  
 Patient visits that included a documented plan of care to address pain  
 
Performance Denominator (PD) Includes:  
 All visits for patients, regardless of age, with a diagnosis of cancer, currently receiving chemotherapy or 
radiation therapy AND  
 
 A visit where a patient reports having pain  
 
Performance Calculation 
 
A (# of patient visits meeting numerator criteria) divided by 
PD (# of patient visits in denominator) 
 
Components for this measure are defined as:  
A  
# of patient visits that included a documented plan of care to address pain  
PD  
# of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation 
therapy who report having pain  
Calculation for Reporting  
For reporting purposes, this measure is calculated by creating a fraction with the following components: Reporting 
Numerator and Reporting Denominator  
Reporting Numerator includes each of the following instances:  
A. Patient visits where a patient reports having pain that included a documented plan of care to address pain  
D. Patient visits where a patient reports having pain that did not include a documented plan of care to address pain  
E. Patient visits that report no pain  
Reporting Denominator (RD) Includes:  
 All patient visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemother-
apy or radiation therapy  
 
Reporting Calculation 
 
A(# of patient visits meeting additional denominator criteria AND meeting numerator criteria) + D(# of patient vis-
its meeting additional denominator criteria NOT meeting numerator criteria) + E (# of patient visits not meeting 
additional denominator criteria) divided by 
RD (# of patient visits in denominator) 
 
A  
# of patient visits where a patient reports having pain that included a documented plan of care to address pain  
D  
# of patient visits where a patient reports having pain that did not include a documented plan of care to address 
pain  
E  
# of patient visits where a patient reports no pain  
RD  
# of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation 
therapy   
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No. Domain Subgroup Indicator Details/ Source 
8 Documenta-
tion 
Care 
Planning 
Documented plan for chemo-
therapy 
American Medical Association and 
American Society of Clinical Oncology 
http://www.ama-
assn.org/ama1/pub/upload/mm/pcpi/onco
logy-worksheets.pdf 
Measure #6 
 
Treatment Summary Communication – Radiation Oncology 
This measure may be used as an Accountability measure. 
 
Clinical Performance Measure  
Numerator: Patients who have a treatment summary* report in the chart that was communicated to the physi-
cian(s) providing continuing care and to the patient within one month of completing treatment  
Definition: *Treatment Summary: a report that includes mention of all of the following components: 1) dose deliv-
ered; 2) relevant assessment of tolerance to and progress towards the treatment goals; and 3)subsequent care plans  
Denominator: All patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or ex-
ternal beam radiation therapy  
Denominator Exceptions:  
Documentation of a patient reason(s) for not communicating the treatment summary report to the physician(s) 
providing continuing care (eg, patient requests that report not be sent) and to the patient within one month of 
completing treatment  
Documentation of a system reason(s) for not communicating the treatment summary report to the physician(s) 
providing continuing care (eg, patient does not have any physician responsible for providing continuing care) and to 
the patient within one month of completing treatment  
Measure: Percentage of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy 
or external beam radiation therapy who have a treatment summary report in the chart that was communicated to 
the physician(s) providing continuing care and to the patient within one month of completing treatment  
The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and 
represent the evidence base for the measure:  
A summary should be generated that accurately describes the treatment process, the doses delivered to the tar-
get/tumor volume and other key organs, relevant assessment of tolerance to and progress towards the treatment 
goals, and subsequent care plans. The style will reflect the radiation oncologist’s individual practice convention and 
the referral provider's needs. The style, content, and detail of this summary must be tailored to the clinical setting 
and prevailing practice norms. It should contain elements that accurately and succinctly reflect the program of care 
administered in a language understandable to the non-radiation oncologist. It is suggested that, the report to the re-
ferring physician include a request for periodic updates on the patient’s progress. These updates will facilitate conti-
nuity of care should the patient require further radiation therapy. (not ranked) (ACR7)  
Rationale for the measure:  
Timely, accurate, and effective communications are critical to quality and value in contemporary medical practices. 
As both a consultant oncologist and the provider of radiation oncology services, the radiation oncologist has a dual 
role. Radiation therapy incorporates the science of complex, integrated treatment delivery and the art of individual 
cancer management. Through written focused reports and direct communications, the contribution of radiation on-
cologists concerning patient care, responsible utilization, and quality are provided, especially to primary care physi-
cians, other oncologists and specialists, and allied healthcare providers (nurses, tumor registrars, quality assurance 
personnel, third-party reviewers, etc). (ACR7)  
Data capture and calculations:  
Calculation for Performance  
For performance purposes, this measure is calculated by creating a fraction with the following components: Nu-
merator, Denominator, and Denominator Exclusions.  
Performance Numerator (A) Includes:  
 Patients who have a treatment summary report in the chart that was communicated to the physician(s) 
providing continuing care and to the patient within one month of completing treatment  
 
Performance Denominator (PD) Includes:  
 All patients, regardless of age, with a diagnosis of cancer AND  
 
 Patients who have undergone brachytherapy or external beam radiation therapy  
 
Performance Denominator Exceptions (C) Include:  
 Documentation of patient reason(s) for not having a treatment summary report in the chart that was 
Generic indicators for process quality in oncological care 
42 LBI-HTA | 2012 
communicated to the physician(s) providing continuing care (eg, patient requests that report not be sent) and to 
the patient within one month of completing treatment  
 
 Documentation of system reason(s) for not having a treatment summary report in the chart that was 
communicated to the physician(s) providing continuing care (eg, patient does not have any physician responsible 
for providing continuing care) and to the patient within one month of completing treatment  
 
Performance Calculation 
 
A (# of patients meeting measure criteria) divided by 
PD (# of patients in denominator) – C (# of patients with valid denominator exclusions) 
 
Components for this measure are defined as:  
A  
# of patients who have a treatment summary report in the chart that was communicated to the physician(s) provid-
ing continuing care and to the patient within one month of completing treatment  
PD  
# of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam ra-
diation therapy  
C  
# of patients with documented patient or system reason(s) for not having a treatment summary report in the chart 
that was communicated to the physician(s) providing continuing care and to the patient within one month of com-
pleting treatment 
 
D. Patients who do not have a treatment summary report in the chart that was communicated to the physician(s) 
providing continuing care and to the patient within one month of completing treatment and there is no docu-
mented reason for not doing so  
 
Reporting Denominator (RD) Includes:  
 All patients, regardless of age, with a diagnosis of cancer AND  
 
 Patients who have undergone brachytherapy or external beam radiation therapy  
 
Reporting Calculation 
A(# of patients meeting numerator criteria) + C(# of patients with valid exclusions) + D(# of patients NOT meet-
ing numerator criteria) divided by 
RD (# of patients in denominator) 
 
Components for this measure are defined as:  
A  
# of patients who have a treatment summary report in the chart that was communicated to the physician(s) provid-
ing continuing care and to the patient within one month of completing treatment  
C  
# of patients who do not have a treatment summary report in the chart that was communicated to the physician(s) 
providing continuing care and to the patient within one month of completing treatment but for whom there is a 
documented patient or system reason for not doing so  
D  
# of patients who do not have a treatment summary report in the chart that was communicated to the physician(s) 
providing continuing care and to the patient within one month of completing treatment and there is no docu-
mented reason for not doing so  
RD  
# of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam ra-
diation therapy  
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No. Domain Subgrou
p 
Indicator Details/ Source 
9 Documentation  Chemotherapy treatment 
summary 
American Medical Association and 
American Society of Clinical Oncology 
http://www.ama-
assn.org/ama1/pub/upload/mm/pcpi/onco
logy-worksheets.pdf 
Measure #5 
 
Treatment Summary Documented and Communicated– Medical Oncology 
This measure may be used as a Quality Improvement measure only. 
 
Clinical Performance Measure  
Numerator: (this numerator has 3 components that must be calculated individually):  
A. Patients who have a chemotherapy treatment summary* documented in the medical record  
B. Patients who have documentation that a chemotherapy treatment summary* was communicated to the patient  
C. Patients who have documentation that a chemotherapy treatment summary* was communicated to the physi-
cian(s) providing continuing care  
 
Definition: *Treatment Summary: a report that includes mention of all of the following components: 1) chemother-
apy treatment delivered (including number of cycles administered, duration, and extent of dose reduction); 2) rea-
son treatment was stopped; 3) major toxicities and/or hospitalizations; 4) treatment response; 5) follow up care and 
relevant providers.  
This measure requires that ALL components listed within the numerator statement be provided in order to meet the 
measure.  
Denominator: All patients, regardless of age, with a diagnosis of cancer who have completed adjuvant chemother-
apy treatment within the 12 month reporting period  
Denominator Exceptions:  
Documentation of a patient reason(s) for not having either a chemotherapy treatment summary documented in the 
medical record OR not having documentation that the chemotherapy treatment summary was communicated to 
the patient and physician(s) providing continuing care (eg, patient requests that report not be sent)  
Documentation of system reason(s) for not having either a chemotherapy treatment summary documented in the 
medical record OR not having documentation that the written chemotherapy treatment summary was provided to 
the patient andphysician(s) providing continuing care  
(eg, patient does not have any physician responsible for providing continuing care)  
This measure requires that ALL components listed within the numerator statement be provided in order to meet the 
measure.  
Measure: Percentage of patients, regardless of age, with a diagnosis of cancer who have completed adjuvant che-
motherapy treatment within the 12 month reporting period who: A) have a chemotherapy treatment summary* 
documented in the medical record; AND B) have documentation that a chemotherapy treatment summary* was 
communicated to the patient; AND C) have documentation that a chemotherapy treatment summary* was com-
municated to the physician(s) providing continuing care  
The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and 
represent the evidence base for the measure:  
The chemotherapy treatment summary should be prepared at the completion of a course of treatment. The core 
elements of a chemotherapy treatment summary are:  
 Chemotherapy treatment delivered, including number of cycles administered, duration, and extent of dose 
reduction  
 Reason treatment was stopped  
 Major toxicities and/or hospitalizations  
 Treatment response  
 Follow up care and relevant providers  
 
This may occur at the end of a course of adjuvant therapy, before a planned surgical resection, or after disease pro-
gression. Treatment breaks, holidays, and minor modifications are not envisioned as triggering preparation of such a 
summary. The treatment plan and summary are not intended to replace detailed chart documentation, including 
complete patient histories or chemotherapy flow sheets. (ASCO)  
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Rationale for the measure:  
Timely, accurate, and effective communications are critical to quality and value in contemporary medical practices. 
This measure is broken into 3 distinct components to encourage sharing of communication about the patient’s 
course of treatment with the patient him/herself, the physician proving continuing care for the patient, and docu-
mented in the medical record. Since each component of the numerator will be scored separately, physicians will 
know exactly which aspect of care may need improvement.  
Data capture and calculations:  
Calculation for Performance  
For performance purposes, this measure is calculated by creating a fraction with the following components: Nu-
merator, Denominator, and Denominator Exclusions.  
Performance Numerator (A) Includes:  
 Patients who have a chemotherapy treatment summary documented in the chart AND who have a docu-
mentation that the written chemotherapy treatment summary was provided to the patient AND who have docu-
mentation that the chemotherapy treatment summary was communicated to the physician(s) providing continuing 
care  
 
Performance Denominator (PD) Includes:  
 All patients, regardless of age, with a diagnosis of cancer AND  
 
 Patients who have completed adjuvant chemotherapy treatment within the 12 month reporting period  
 
Performance Denominator Exceptions (C) Include:  
 Documentation of patient reason(s) for not having either a chemotherapy treatment summary docu-
mented in the chart OR not having documentation that the chemotherapy treatment summary was communicated 
to the patient OR not having documentation that the chemotherapy treatment summary was communicated to the 
physician(s) providing continuing care (eg, patient requests that report not be sent)  
 
 Documentation of system reason(s) for not having either a chemotherapy treatment summary docu-
mented in the chart OR not having documentation that the written chemotherapy treatment summary was pro-
vided to the patient OR not having documentation that the chemotherapy treatment summary was communicated 
to the physician(s) providing continuing care (eg, patient does not have any physician responsible for providing 
continuing care)  
 
Performance Calculation 
 
A (# of patients meeting measure criteria) divided by 
PD (# of patients in denominator) – C (# of patients with valid denominator exclusions) 
Components for this measure are defined as:  
A  
# of patients who have a chemotherapy treatment summary documented in the chart AND who have a documenta-
tion that the written chemotherapy treatment summary was provided to the patient AND who have documenta-
tion that the chemotherapy treatment summary was communicated to the physician(s) providing continuing care  
PD  
# of patients with a diagnosis of cancer who have completed adjuvant chemotherapy treatment within the 12 
month reporting period  
C  
# of patients with documented patient or system reason(s) for not having either a chemotherapy treatment sum-
mary documented in the chart OR not having documentation that the written chemotherapy treatment summary 
was provided to the patient OR not having documentation that the chemotherapy treatment summary was com-
municated to the physician(s) providing continuing care  
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No. Domain Subgroup Indicator Details/ Source 
10 Reporting  Synoptic Pathology Reporting Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portal
Id=89621&pageId=92533  
 
Synoptic Pathology Reporting 
Definition  
Percent of 5 common cancer pathology reports submitted in discrete synoptic format, as per the Col-
lege of American Pathologist’s (CAP) inclusion criteria  
5 common cancers sites are: Invasive Breast, Colorectal, Prostate, Endometrium and Lung  
Calculation  
Number reports received in discrete synoptic format  
 
Total number of pathology reports received in either discrete synop-
tic or narrative format  
X 100 
=  
Synoptic Rate 
(%)  
 
Analysis  
 Discrete synoptic reporting rate by pathology submitting facility LHIN (reporting in either 
discrete synoptic or narrative format in 2010 
Considerations 
 North East LHIN, for specified timeframe, does not include the Ottawa Hospital. The Ottawa 
Hospital has since gone live in January 2011 
Technical Spe-
cifications  
 This report utilizes all pathology resection reports received in discrete synoptic data format 
from Ontario hospitals through Cancer Care Ontario’s pathology reporting database during 
the defined reporting period.  The source data set excludes the following: 
 All Non cancer cases 
 ICDO-3 behaviours of 0 (benign), 1 (borderline), 6 (metastatic), and 2 (in situ). 
 Report with a status of "K" (consult of external hospital) 
 All report types other than surgical pathology (“P”) reports (i.e. biopsies are excluded) 
 Reports not coded at time of analysis 
 Reports from private labs (institution codes of 9300 or greater) and pediatric hospitals 
 Reports in which the “Specimen Type” contains any of the following terms: 
o For prostate: TURPs, Chips, Transurethral, Prostate TUR, cystoprostatectomies; 
o For colorectal cancer: polyp, rectal abscess, rectal polyp, polypectomy 
o For endometrium: uterine curettings 
 Reports in which the “Specimen Taken” date was before go-live date plus two days  
**Important Note Regarding the Discrete Synoptic Reporting Indicator:  The Synoptic Pathology Re-
porting target is set at 90% rather than 100%, which allows a 10% window for those rare cases that 
do not fit the current CAP checklists and which CCO cannot exclude automatically.  Please be aware of 
this when reviewing/interpreting the results for the synoptic pathology reporting indicator.  Examples 
of the rare instances where the current CAP checklist DDF templates may not or cannot be appropri-
ately utilized by the reporting pathologists include: 
 Microinvasion breast cancer 
 Unusual histologies (i.e. sarcomas, phyllodes tumour, carcinosarcoma, neuroendocrine tu-
mours) 
 Re-excisions 
 Recurrent tumours 
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 Axillary node dissection only 
 Reports waiting for consultation (if uncertainty of diagnosis of cancer) 
1 College of American Pathologists. An overview of the College of American Pathologists cancer check-
lists, 2009. Available at: 
http://www.cap.org/apps/docs/snomed/CAP_Cancer_Checlkists_Overview_090115.pdf. Accessed March 
13, 2009. 
Numerator  
 All 5 common cancer resection reports received in discrete synoptic format (level 5 or 6) in 
2010 
Denominator   All 5 common cancer resection reports received by CCO in 2010  
Data Sources   Pathology Information Management System, Cancer Care Ontario, as of January 2011 
Data Availabili-
ty & Limitati-
ons  
 N/A 
 
 
 
No. Domain Subgroup Indicator Details/ Source 
11 Guideline 
adherence 
 Compliance to guidelines NPK Monitor 2009 
http://www.npknet.nl/2210-p-1908  
 
Compliance to guidelines 
Indicators 
Compliance with guidelines, specified by tumour type and stage. Several of these guidelines are presented as an indica-
tor in the Monitor 2009.  
For breast cancer:  
  Performing breast-conserving surgery (lumpectomy) for small breast tumours (T1 N0,1,2 M0) on women 
from 15 to 75 years old.  
For colon cancer: 
 The percentage of patients operated on, whereby a minimum of 10 lymph nodes are examined/removed via 
resection (only for stage I or II tumours).    The percentage of patients operated on who are under 80 years of age with a pathological stage III tumour, 
and who were administered adjuvant chemotherapy.  
For rectal cancer:  
 The percentage of patients operated on who are under 80 years of age and have received preoperative radio-
therapy.  
For bladder cancer: 
  The percentage of patients operated on (cystectomy) in whom radical lymph node dissection was performed 
(a minimum of 10 lymph nodes are removed).  
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Objective  
The NPK stipulates that every patient is entitled to optimal and timely diagnosis, treatment and care in accordance 
with the most current guidelines. The guideline for small breast tumours favours breast-conserving surgery, which 
aims to achieve an “excellent” cosmetic result and optimal locoregional tumour control (www.oncoline.nl).  
Two guidelines are provided for colon cancer. The first guideline aims at the highest possible percentage of patients 
operated on with a stage I or II tumour, whereby a minimum of 10 lymph nodes are examined/removed.  
The second guideline concerns the administration of adjuvant chemotherapy and aims at the highest possible percent-
age of patients with a pathological stage III tumour who receive adjuvant chemotherapy.  
 
The guideline for rectal cancer favours preoperative radiotherapy over postoperative radiotherapy and indicate preop-
erative radiotherapy for all T2-T4 tumours (www.oncoline.nl). The aim is therefore a high percentage of patients oper-
ated on who have undergone preoperative radiotherapy (www.oncoline.nl).  
The guideline for bladder cancer aims at the highest possible percentage of patients operated on, in whom radical 
lymph node dissection was performed (i.e. a minimum of 10 lymph nodes are examined).  
 
Technical information Definitions  
 Compliance with guidelines requires that relevant indicators be specified for each tumour type and stage. One such 
example is the application of breast-conserving surgery for small (T1) invasive primary breast tumours among 
women between the ages of 15 and 75.  
Two indicators are provided for colon cancer. The first is the percentage of patients with a stage I or II tumour, 
whereby a minimum of 10 lymph nodes are removed/examined during resection. The second indicator for colon can-
cer represents the percentage of patients that have had a resection and received adjuvant chemotherapy. Only those 
patients under the age of 80 and with a stage III tumour are taken into account for this.  
For rectal cancer, the indicator is the percentage of patients under the age of 80 who have received preoperative ra-
diotherapy. All stages are taken into account for this. Rectal sigmoid tumours are not taken into account.  
The indicator of bladder cancer is the percentage of patients in whom radical lymph node dissection was performed 
(a minimum of 10 lymph nodes are removed as a result of a cystectomy).  
 
Data source  
 The data were gathered from the Netherlands Cancer Registry (NKR) of the Association of Comprehensive Cancer 
Centres (VIKC). This registry contains data from the eight comprehensive cancer centres and comprises the entire 
Dutch population (‘population-based’). Since 2008, data have been directly entered into the nationwide registry by 
specially trained staff who compile information from patient files in hospitals based on reports from the Dutch na-
tional pathology information system (PALGA). Once a year, the data are supplemented with information from the 
Dutch National Medical Registration (LMR) and other sources, if available. This ensures that the registry contains 
information on every patient diagnosed with cancer and on any cancer diagnosed. An estimated 95% of all cancer 
cases in the Netherlands are recorded in the database. 
 
Remarks upon data  
  The stage of the tumour is crucial in evaluating the guidelines.   In addition, the patient’s age and other disorders (comorbidity) should be taken into consideration when 
evaluating the application of specific treatments.   If the patient is being treated in a trial, this should also be considered therapy in accordance with the 
guidelines. However, these data are not (yet) included in the cancer registry. 
 
 
 
 
No. Domain Subgroup Indicator Details/ Source 
12 Clinical trial 
participation 
 Participation in Clinical Trials Greenberg (2005), table 3 
 
Strategic goal: Increase use of evidence and innovation in decision-making 
Indicator: Clinical trial participation 
Definition: Number of patients recruited to clinical trials for chemotherapy, radiotherapy, and interven-
tions studies by hospital 
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No. Domain Subgroup Indicator Details/ Source 
13 Multidiscipli-
narity 
 Patient discussed at multidisci-
plinary forum 
Most far reaching concept: Cancer Qual-
ity Council Ontario 
http://www.cqco.ca/cms/One.aspx?portal
Id=89621&pageId=92559  
 
 
Patient discussed at multidisciplinary forum: MCCs Adherence to Standards 
Definition The percentage of reported MCCs that are meeting the minimum standards criteria  
Calculation 
Number of MCC Standards criteria met 
 
Total number of criteria required by MCCs 
Standards 
X 100 
=  
Percentage of MCCs meeting mini-
mum standards 
 
Analysis 
 For Q3 2009/10 and Q3 2010/11  
 By LHIN 
 For specific disease site attendance criteria, please go 
to: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=63113  
*Regions will not be penalized if a medical oncologist does not attend a Gynaecology MCC. Therefore, 
the denominator is either 8 or 9. 
Considerations 
 Percentages are based on low volume 
 We have restated FY09/10 results. In order to improve and maintain consistency the 
FY09/10 results have been reinstated and measured by the same methodology as FY10/11 
results. Most regions will have a smaller hospital denominator.  
Technical Speci-
fications 
 Quarterly MCC reporting process where the Regional MCC Coordinator submits and vali-
dates MCC performance 
Exclusions: 
 NA 
Numerator  Number of MCC Standards Criteria met  
Denominator  Total number of criteria required by MCCs Standards  
Data Sources  MCC Tracker Tool Self reported in MCC Data Excel Template, Cancer Care Ontario 
Data Availability 
& Limitations 
 Data is reported for Q3 2009/10 and Q3 2010/11 to CCO 
Limitations: 
 Not all hospitals are reporting MCCs data  
 
Multidisciplinary Cancer Conference Standards under 
https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14318  
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14 Multidisciplinar-
ity 
Communi-
cation 
Treatment summary American Medical Association and American 
Society of Clinical Oncology 
http://www.ama-
assn.org/ama1/pub/upload/mm/pcpi/oncolog
y-worksheets.pdf 
Measure #5 and # 6 
 
 
Treatment Summary Communication – Radiation Oncology 
This measure may be used as an Accountability measure. 
 
Clinical Performance Measure  
Numerator: Patients who have a treatment summary* report in the chart that was communicated to the physi-
cian(s) providing continuing care and to the patient within one month of completing treatment  
Definition: *Treatment Summary: a report that includes mention of all of the following components: 1) dose deliv-
ered; 2) relevant assessment of tolerance to and progress towards the treatment goals; and 3)subsequent care plans  
Denominator: All patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or ex-
ternal beam radiation therapy  
Denominator Exceptions:  
Documentation of a patient reason(s) for not communicating the treatment summary report to the physician(s) 
providing continuing care (eg, patient requests that report not be sent) and to the patient within one month of 
completing treatment  
Documentation of a system reason(s) for not communicating the treatment summary report to the physician(s) 
providing continuing care (eg, patient does not have any physician responsible for providing continuing care) and to 
the patient within one month of completing treatment  
Measure: Percentage of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy 
or external beam radiation therapy who have a treatment summary report in the chart that was communicated to 
the physician(s) providing continuing care and to the patient within one month of completing treatment  
The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and 
represent the evidence base for the measure:  
A summary should be generated that accurately describes the treatment process, the doses delivered to the tar-
get/tumor volume and other key organs, relevant assessment of tolerance to and progress towards the treatment 
goals, and subsequent care plans. The style will reflect the radiation oncologist’s individual practice convention and 
the referral provider's needs. The style, content, and detail of this summary must be tailored to the clinical setting 
and prevailing practice norms. It should contain elements that accurately and succinctly reflect the program of care 
administered in a language understandable to the non-radiation oncologist. It is suggested that, the report to the re-
ferring physician include a request for periodic updates on the patient’s progress. These updates will facilitate conti-
nuity of care should the patient require further radiation therapy. (not ranked) (ACR7)  
Rationale for the measure:  
Timely, accurate, and effective communications are critical to quality and value in contemporary medical practices. 
As both a consultant oncologist and the provider of radiation oncology services, the radiation oncologist has a dual 
role. Radiation therapy incorporates the science of complex, integrated treatment delivery and the art of individual 
cancer management. Through written focused reports and direct communications, the contribution of radiation on-
cologists concerning patient care, responsible utilization, and quality are provided, especially to primary care physi-
cians, other oncologists and specialists, and allied healthcare providers (nurses, tumor registrars, quality assurance 
personnel, third-party reviewers, etc). (ACR7)  
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Data capture and calculations:  
Calculation for Performance  
For performance purposes, this measure is calculated by creating a fraction with the following components: Nu-
merator, Denominator, and Denominator Exclusions.  
Performance Numerator (A) Includes:  
 Patients who have a treatment summary report in the chart that was communicated to the physician(s) 
providing continuing care and to the patient within one month of completing treatment  
 
Performance Denominator (PD) Includes:  
 All patients, regardless of age, with a diagnosis of cancer AND  
 
 Patients who have undergone brachytherapy or external beam radiation therapy  
 
Performance Denominator Exceptions (C) Include:  
 Documentation of patient reason(s) for not having a treatment summary report in the chart that was 
communicated to the physician(s) providing continuing care (eg, patient requests that report not be sent) and to 
the patient within one month of completing treatment  
 
 Documentation of system reason(s) for not having a treatment summary report in the chart that was 
communicated to the physician(s) providing continuing care (eg, patient does not have any physician responsible 
for providing continuing care) and to the patient within one month of completing treatment  
 
Performance Calculation 
 
A (# of patients meeting measure criteria) divided by 
PD (# of patients in denominator) – C (# of patients with valid denominator exclusions) 
 
Components for this measure are defined as:  
A  
# of patients who have a treatment summary report in the chart that was communicated to the physician(s) provid-
ing continuing care and to the patient within one month of completing treatment  
PD  
# of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam ra-
diation therapy  
C  
# of patients with documented patient or system reason(s) for not having a treatment summary report in the chart 
that was communicated to the physician(s) providing continuing care and to the patient within one month of com-
pleting treatment  
Calculation for Reporting  
For reporting purposes, this measure is calculated by creating a fraction with the following components: Reporting 
Numerator and Reporting Denominator  
Reporting Numerator includes each of the following instances:  
A. Patients who have a treatment summary report in the chart that was communicated to the physician(s) provid-
ing continuing care and to the patient within one month of completing treatment  
C. Documented patient or system reason(s) for not having a treatment summary report in the chart that was com-
municated to the physician(s) providing continuing care and to the patient within one month of completing treat-
ment  
 
D. Patients who do not have a treatment summary report in the chart that was communicated to the physician(s) 
providing continuing care and to the patient within one month of completing treatment and there is no docu-
mented reason for not doing so  
Reporting Denominator (RD) Includes:  
 All patients, regardless of age, with a diagnosis of cancer AND  
 
 Patients who have undergone brachytherapy or external beam radiation therapy  
 
Reporting Calculation 
 
A(# of patients meeting numerator criteria) + C(# of patients with valid exclusions) + D(# of patients NOT meet-
ing numerator criteria) divided by 
RD (# of patients in denominator) 
 
Components for this measure are defined as:  
A  
# of patients who have a treatment summary report in the chart that was communicated to the physician(s) provid-
ing continuing care and to the patient within one month of completing treatment  
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C  
# of patients who do not have a treatment summary report in the chart that was communicated to the physician(s) 
providing continuing care and to the patient within one month of completing treatment but for whom there is a 
documented patient or system reason for not doing so  
D  
# of patients who do not have a treatment summary report in the chart that was communicated to the physician(s) 
providing continuing care and to the patient within one month of completing treatment and there is no docu-
mented reason for not doing so  
RD  
# of patients, regardless of age, with a diagnosis of cancer who have undergone brachytherapy or external beam ra-
diation therapy  
 
 
 
No. Domain Subgroup Indicator Details/ Source 
15 Pain 
management 
Assess-
ment 
Pain Assessment Georgia Cancer Coalition 
Lorenz (2006): appendix F1 
 
Description of Indicator: Routine assessment of pain. 
Denominator: Number of cancer patient encounters. 
Numerator: Number of cancer patient encounters where patient where patient was assessed for 
pain. 
Disease: Mixed cancer 
 
 
No. Domain Subgroup Indicator Details/ Source 
16 Pain 
management 
Assess-
ment 
Pain intensity quantified University Health Consortium 
Lorenz (2006): appendix F1 
 
Description of Measure: Routine inpatient pain assessment with a numeric scale. 
Denominator: Adults > or = 18 years of age, with admission for CHF (DRG 127), Cancer (DRG 
82, 203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 475, 483) AND length of stay > 4 
days, 2 prior admissions for any cause in preceding 12 months in the hospital , AND reported pain 
within the 1st 48 hours of admission. 
Numerator: Persons assessed with a numeric pain scale. 
Disease: CHF, Mixed cancer, HIV, Mixed respiratory diseases 
 
 
No. Domain Subgroup Indicator Details/ Source 
17 Pain 
management 
Treat-
ment 
Pain Treatment RAND 
Lorenz (2006): appendix F1 
 
Description of Measure: Responsive pain treatment. 
Denominator: All cancer patients whose pain is uncontrolled. 
Numerator: Patients offered a change in pain management within 24hours of the pain complaint. 
Disease: Mixed cancer 
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No. Domain Subgroup Indicator Details/ Source 
18 Dyspnea 
management 
Treat-
ment 
Dyspnea treatment University Health Consortium 
Lorenz (2006): appendix F2 
 
Description of Measure: Timely treatment of inpatient dyspnea. 
Denominator: Adults > or = 18 years of age, with admission for CHF (DRG 127), Cancer (DRG 
82, 203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 475, 483) AND length of stay > 4 
days, 2 prior admissions for any cause in preceding 12 months in the hospital, AND reported dysp-
nea within the 1st 48 hours of admission. 
Numerator: Dyspnea relief or reduction within 48 hours of admission. 
Disease: CHF, Mixed cancer, HIV, Mixed respiratory diseases 
 
 
No. Domain Subgroup Indicator Details/ Source 
19 Depression/ 
Emotional 
well-being 
Assess-
ment 
Assessment emotional well-
being 
University Health Consortium 
Lorenz (2006): appendix F3 
 
Description of Measure: Regular assessment for psychosocial well-being. 
Denominator: Adults > or = 18 years of age, with admission for CHF (DRG 127), Cancer (DRG 
82, 203, 172, 274, 346, 10) HIV (DRG 489) OR respiratory (DRG 475, 483) AND length of stay > 4 
days, 2 prior admissions for any cause in preceding 12 months in the hospital. 
Numerator: Formal psychosocial assessment up to 1 year prior to admission during a previous hos-
pitalization OR within 4 days of index admission. 
Disease: CHF, Mixed cancer, HIV, Mixed respiratory diseases 
 
 
No. Domain Subgroup Indicator Details/ Source 
20 General 
processes 
Appropriate utiliza-
tion radioation 
treatment 
Radiation Treatment 
Utilization 
Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portal
Id=89621&pageId=92612  
 
 
Radiation treatment utilization 
Definition Proportion of patients receiving radiation treatment at any time during their illness  
Calculation 
 Estimated using Multi-cohort Current Utilization Table (MCUT) method.  
Reference:  
 J. Zhang-Salomons and W.J. Mackillop, “Estimating the lifetime utilization rate of radio-
therapy in caner patients: The Multicohort Current Utilization Table (MCUT) method”, 
Computer Method and Programs in Biomedicine, 92, (2008) 99-108.  
Analysis 
 For years from November 1 to October 31, 2004/05, 2005/2006, 2006/07, 2007/2008, 
2008/09, 2009/2010. 
 By LHIN and overall 
Considerations  
Technical Specifi-
cations 
 Benchmark rates were calculated previously using 2001-2002 data, based on the assump-
tion that the appropriate rate could be approximated by the rates observed in communi-
ties where there are no barriers to access to care and no financial incentive to over treat 
patients.  
“No barriers” is measured by wait time (counties in which the wait time is shorter than the provin-
cial average). “No financial incentive to over treat patient” means that the benchmark rates were 
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calculated when radiation oncologists were paid a standard salary. They are now in private opera-
tion and fee for service is applied. 
 Percentage shortfall in the use of radiation treatment was calculated as the difference be-
tween observed rate and the rate in the benchmark communities, divided by the bench-
mark rate.  
Exclusions: 
 Radiotherapy given to in-situ and non-malignant diseases were excluded. 
Numerator  Radiotherapy given to cancer patients for treatment of cancer 
Denominator  Cancer cases diagnosed in Ontario as identified through the Ontario Cancer Registry 
Data Sources 
 Activity Level Reporting, Cancer Care Ontario 
 Ontario Cancer Registry, Cancer Care Ontario 
 Historical radiotherapy data from OPIS and PMH 
Data Availability 
& Limitations 
 Information on radiation treatment was incomplete for the county of Kenora, because a 
large proportion of patients residing in Kenora travel to the neighbouring province for 
treatment. As a result, the utilization rate in Kenora was not reported. 
Limitations: 
 The linkage rate of the radiation treatment data to the Ontario Cancer Registry is more 
than 99%. Assuming all the unlinked cases were attributable to the cancer cases in the 
Ontario Cancer Registry, this could under-estimate the utilization rate by less than 0.5%.
 
 
 
No. Domain Subgroup Indicator Details/ Source 
21 Advanced 
Care Plan-
ning ACP 
Preferences 
Assessment 
Regular assessment of prefer-
ences in an ICU 
 
Assessing the Care Of Vulnerable Elders 
ACOVE 
Lorenz (2006): appendix F4 
 
Description of Measure: Regular assessment of preferences in an ICU. 
IF a vulnerable elder is admitted directly to the intensive care unit from an outpatient or ER set-
ting and survives 48 hours, THEN within 48 hours of admission, the medical record should docu-
ment that the patient's preferences for care have been considered or that these preferences could 
not be elicited or are unknown. 
Denominator: All vulnerable elderly patients admitted directly to the ICU from an outpatient or 
ER setting and surviving 48 hours. 
Numerator: Number of vulnerable elders admitted directly to the intensive care unit from an out-
patient or ER setting and surviving 48 hours with documentation in the medical record that the pa-
tient's preferences for care have been considered or that these preferences could not be elicited or 
are unknown within 48 hours of admission. 
Disease: Mixed disease 
 
 
No. Domain Subgroup Indicator Details/ Source 
22 ACP Preferences 
Follow-up 
Care consistency with docu-
mented care preferences 
Assessing the Care Of Vulnerable Elders 
ACOVE 
Lorenz (2006): appendix F4 
 
Description of Indicator: Care consistency with documented care preferences.If a vulnerable elder 
has specific treatment preferences (e.g., a do-not-resuscitate order, no tube feeding, or no hospital 
transfer) documented in a medical record, THEN these treatment preferences should be followed. 
Denominator: All vulnerable elderly patients in any health care setting with specific treatment 
preferences documented in their medical record. 
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Numerator: Number of vulnerable elders with specific treatment preferences documented in their 
medical record with those treatment preferences having been followed. 
Disease: Mixed disease 
 
 
No. Domain Subgroup Indicator Details/ Source 
23 End-of-life  Death in acute-care bed Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portal
Id=89621&pageId=92397  
 
 
End of Life Care – Death in Hospital 
Definition Percentage of cancer patients who died in acute care hospital  
Calculation 
Number of Cancer patients who died in hospital 
 
Target Population (number of deaths) 
X 100 =  Percent of deaths in hospital 
 
Analysis  For calendar years 2004 to 2007, by calendar year and LHIN 
Considerations 
 These results do not assess the quality of end-of-life care in detail. For example, the absence 
of emergency department visits does not necessarily mean good quality care. Some patients 
may not have visited the emergency department but may still have experienced poor symp-
tom control or psychological distress. Individual palliative care patients may have specific 
needs or require specific expertise that is not routinely available in the home.  
Technical Speci-
fications 
 Cause of death from Cancer defined by the following ICD9 diagnosis codes from the Ontario 
Cancer Registry: 
Head and Neck (140-149,160,161) 
Female Breast (174) 
Lung (162) 
Prostate (185) 
Ovary (183) 
Colorectal (153,154) 
CNS (191) 
Lymphoma/Leukemia (200-208) 
Other GU/ Gyne (179-182,184,186-189) 
Melanoma/Sarcoma (170-172, 176) 
Other GI (150-152, 155-159) 
Metastases (196-199) 
Other (163-165, 175,190,192-195) 
Non-melanoma skin (173) 
 Diagnosis on death certificate must be a cancer diagnosis 
 Death in hospital defined by discharge disposition of “death” 
 Local Health Integrated Network (LHIN) assignment is based on Postal Code Conversion file 
(PCCF+), version 5e  
Exclusions: 
 Invalid HINs 
 Death certificate only patient 
 Age <20 
 Death within 30 days of major cancer surgery 
 Death outside of Ontario 
Numerator  Total number of cancer patients who died in hospital 
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Definition Percentage of cancer patients who died in acute care hospital  
Denominator  Total number of deaths related to cancer 
Data Sources 
 Ontario Cancer Registry, Cancer Care Ontario 
 Discharge Abstract Data base, Canadian Institute for Health Information 
 Registered Person Database (RPDB), Ministry of Health and Long-Term Care 
Data Availabili-
ty & Limitations 
 There is no palliative care minimum dataset that is being consolidated / collected by care 
giver teams. Such a database could help understand the demand for end-of-life care services 
and activities.  
 Non-medical data in CIHI and NACRS has been found to be very accurate 
(http://www.ices.on.ca/file/CIHI_DAD_Reabstractors_study.pdf); Canadian Institute for 
Health Information, Data Quality Documentation, Discharge Abstract Database, 2007–
2008—Executive Summary (Ottawa, Ont.: CIHI, 2008, Canadian Institute for Health Infor-
mation, CIHI Data Quality Study of Ontario Emergency Department Visits for Fiscal Year 
2004–2005—Executive Summary (Ottawa: CIHI, 2008).  
 The cohort definition requires information about cause of death. There is a delay in the up-
date of this variable in the OCR. Consequently, the most updated cohort only includes up to 
2007.  
 
 
No. Domain Subgroup Indicator Details/ Source 
24 End-of-life  Emergency department visit Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portal
Id=89621&pageId=92397 
 
 
End of Life Care – Visits to Emergency 
Definition Percentage of cancer patients who visited the emergency department up to two weeks before death  
Calculation 
Number of Cancer patients who vis-
ited emergency 
 
Target Population (number of 
deaths 
X 100 
=  
Percentage of cancer patients who visited the 
ER up to two weeks before death 
 
Analysis 
 For calendar years 2004 to 2007 ,  
 Percentage of cancer patients, by calendar year and LHIN 
Considerations 
 These results do not assess the quality of end-of-life care in detail. For example, the absence 
of emergency department visits does not necessarily mean good quality care. Some patients 
may not have visited the emergency department but may still have experienced poor symp-
tom control or psychological distress. Individual palliative care patients may have specific 
needs or require specific expertise that is not routinely available in the home.  
Technical Speci-
fications 
 Cause of death from Cancer defined by the following ICD9 diagnosis codes from the Ontario 
Cancer Registry: 
Head and Neck (140-149,160,161) 
Female Breast (174) 
Lung (162) 
Prostate (185) 
Ovary (183) 
Colorectal (153,154) 
CNS (191) 
Lymphoma/Leukemia (200-208) 
Other GU/ Gyne (179-182,184,186-189) 
Melanoma/Sarcoma (170-172, 176) 
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Definition Percentage of cancer patients who visited the emergency department up to two weeks before death  
Other GI (150-152, 155-159) 
Metastases (196-199) 
Other (163-165, 175,190,192-195) 
Non-melanoma skin (173) 
 Diagnosis on death certificate must be a cancer diagnosis 
 ER visit must be within 14 days of death date 
 Local Health Integrated Network (LHIN) assignment is based on Postal Code Conversion file 
(PCCF+), version 5e  
 
Exclusions: 
 Invalid HINs 
 Death certificate only patient 
 Age <20 
 Death within 30 days of major cancer surgery 
 Death outside of Ontario 
 Patient in acute care all 14 days prior to death 
Numerator  Total number of cancer patients who visited the emergency room within 14 days of death 
Denominator  Total number of deaths related to cancer 
Data Sources 
 Ontario Cancer Registry, Cancer Care Ontario 
 National Ambulatory Care Reporting System, Canadian Institute for Health Information 
 Registered Persons Data Base, Ministry of Health and Long-Term Care 
Data Availabili-
ty & Limitations 
 There is no palliative care minimum dataset that is being consolidated / collected by care 
giver teams. Such a database could help understand the demand for end-of-life care services 
and activities.  
 Non-medical data in CIHI and NACRS has been found to be very accurate 
(http://www.ices.on.ca/file/CIHI_DAD_Reabstractors_study.pdf); Canadian Institute for 
Health Information, Data Quality Documentation, Discharge Abstract Database, 2007–
2008—Executive Summary (Ottawa, Ont.: CIHI, 2008, Canadian Institute for Health Infor-
mation, CIHI Data Quality Study of Ontario Emergency Department Visits for Fiscal Year 
2004–2005—Executive Summary (Ottawa: CIHI, 2008).  
 For the analysis of emergency department visit rates, data do not provide information 
about the appropriateness of the visit.  
 The cohort definition requires information about cause of death. There is a delay in the up-
date of this variable in the OCR. Consequently, the most updated cohort only includes up to 
2007.  
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No. Domain Subgroup Indicator Details/ Source 
25 End-of-life  Intensive care unit admission Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portal
Id=89621&pageId=92397 
 
 
End of Life Care – ICU 
Definition Percentage of cancer patients who were admitted to the ICU in the last two weeks of life  
Calculation 
Number of Cancer patients who were admit-
ted to the ICU in the last two weeks of life 
 
Total patients who died of cancer 
X 
100 
=  
Percentage of cancer patients admit-
ted to the ICU in the last two weeks 
of life 
 
Analysis 
 For calendar years 2004 to 2007 ,  
 Percentage of cancer patients who died of cancer, by calendar year and LHIN 
Considerations 
 These results do not assess the quality of end-of-life care in detail. For example, the absence 
of emergency department visits does not necessarily mean good quality care. Some patients 
may not have visited the emergency department but may still have experienced poor symp-
tom control or psychological distress. Individual palliative care patients may have specific 
needs or require specific expertise that is not routinely available in the home.  
Technical Speci-
fications 
 Cause of death from Cancer defined by the following ICD9 diagnosis codes from the Ontario 
Cancer Registry: 
Head and Neck (140-149,160,161) 
Female Breast (174) 
Lung (162) 
Prostate (185) 
Ovary (183) 
Colorectal (153,154) 
CNS (191) 
Lymphoma/Leukemia (200-208) 
Other GU/ Gyne (179-182,184,186-189) 
Melanoma/Sarcoma (170-172, 176) 
Other GI (150-152, 155-159) 
Metastases (196-199) 
Other (163-165, 175,190,192-195) 
Non-melanoma skin (173) 
 Diagnosis on death certificate must be a cancer diagnosis 
 The ICU visits are captured by Discharge Abstract Database. ICU stays were identified using 
ICU admit date (scuadmdate1-6), and ICU discharge date (scuddate1-6). 
 ICU admission must be within 14 days of death date 
 Local Health Integrated Network (LHIN) assignment is based on Postal Code Conversion file 
(PCCF+), version 5e  
 
Exclusions: 
 Invalid HINs 
 Death certificate only patient 
 Age <20 
 Death within 30 days of major cancer surgery 
 Death outside of Ontario 
Numerator  Number of Cancer patients who were admitted to the ICU in the last two weeks of life 
Denominator  Total number of deaths related to cancer 
Data Sources  Discharge Abstract Database, Canadian Institute for Health Information 
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 Ontario Cancer Registry, Cancer Care Ontario 
 Registered Person Database (RPDB), Ministry of Health and Long-Term Care 
Data Availabili-
ty & Limitations 
 There is no palliative care minimum dataset that is being consolidated / collected by care 
giver teams. Such a database could help understand the demand for end-of-life care services 
and activities.  
 Non-medical data in CIHI and NACRS has been found to be very accurate 
(http://www.ices.on.ca/file/CIHI_DAD_Reabstractors_study.pdf); Canadian Institute for 
Health Information, Data Quality Documentation, Discharge Abstract Database, 2007–
2008—Executive Summary (Ottawa, Ont.: CIHI, 2008, Canadian Institute for Health Infor-
mation, CIHI Data Quality Study of Ontario Emergency Department Visits for Fiscal Year 
2004–2005—Executive Summary (Ottawa: CIHI, 2008).  
 The cohort definition requires information about cause of death. There is a delay in the up-
date of this variable in the OCR. Consequently, the most updated cohort only includes up to 
2007. 
 
 
 
No. Domain Subgroup Indicator Details/ Source 
26 End-of-life  Chemotherapy in the last two 
weeks of life 
Cancer Quality Council Ontario 
http://www.cqco.ca/cms/One.aspx?portal
Id=89621&pageId=92397 
 
 
Chemotherapy in the Last Two Weeks of Life 
Definition Percentage of patients who died of cancer who had chemotherapy in the last 2 weeks of life 
Calculation 
Patients with at least one chemotherapy 
claim with service date within the last 14 
days of life. 
 
All patients in the cohort 
X 
100 
=  
 
Percentage of patients who died of 
cancer who had chemotherapy in the 
last 2 weeks of life 
 
Analysis 
 For calendar years 2003 to 2007 
 Analyses by LHIN  
 Analyses by disease site 
 Analyses by sex and by age 
Considerations 
 Since physicians may forget to submit a claim for supervising the delivery of chemotherapy, 
the observed rate may under-represent the real rate. This effect is likely small. These claims 
only represent intravenous chemotherapy and do not include hormonal treatment.  
Technical Speci-
fications 
 Cohort: the Ontario Cancer Registry (OCR) was used to identify all patients who died of 
cancer, in 2003-2007, as indicated by the death certificate. When more than one record was 
present we chose the cause of death as the record which matched the registration diagno-
sis. Cases were excluded if: 1) the diagnosis of cancer was based solely on the death certifi-
cate; 2) the death occurred within 30 days of a major operative procedure; 3) the insurance 
number was not valid during the last 6 months of life; 4) the patient died outside of On-
tario; 5) the patient was younger than 20 years of age. 
 Chemotherapy use: claims with OHIP fee codes indicating the delivery of chemotherapy. 
Numerator  Patients with at least one chemotherapy claim with service date within the last 14 days of life. 
Denominator  All patients in the cohort. 
Data Sources 
 Ontario Cancer Registry, Cancer Care Ontario  
 Ontario Health Insurance Plan database, Ministry of Health and Long-Term Care  
 Registered Persons Data Base, Ministry of Health and Long-Term Care  
Data Availability  The cohort definition requires information about cause of death. There is a delay in the up-date of this variable in the OCR. Consequently, the most updated cohort only includes up to 
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& Limitations 2007.  
 These claims would only represent the delivery of chemotherapy and would not potentially 
be submitted for some other kind of activity. No observations can be made about the type 
of chemotherapy that is give.  
 
 
No. Domain Subgroup Indicator Details/ Source 
27 End-of-life Hospice/ 
Palliative 
care 
Hospice enrolment National Quality Forum 
NQF (2009a), A-14 
 
Not admitted to hospice 
Symptom Management and End-of-Life Care, Surveillance Measure 
 
Intellectual Property Owner: Dana-Faber Cancer Institute 
Numerator: Patients who died from cancer without being admitted to hospice. Those without 
claims in Medicare HOSPICE file. 
Denominator: Patients who died from cancer. 
Inclusions and/or Exclusions: None. 
 
 
No. Domain Subgroup Indicator Details/ Source 
28 End-of-life Hospice Admitted to hospice for less 
than 
National Quality Forum 
NQF (2009a), A-14 
 
Admitted to hospice for less than three days 
Symptom Management and End-of-Life Care, Surveillance Measure 
 
Intellectual Property Owner: Dana-Faber Cancer Institute 
Numerator: Patients who died from cancer and spent fewer than three days in hospice. 
Medicare HOSPICE file only: Subtracted hospice admission date (admitdate)from death date vari-
able to get hospice length of stay. 
Denominator: Patients who died from cancer. 
Inclusions and/or Exclusions: None. 
 
 
No. Domain Subgroup Indicator Details/ Source 
29 End-of-life Hospice Family evaluation of hospice 
care 
National Quality Forum 
NQF (2009a), A-9 
Details on family evaluation survey: NQF 
(2009a), figure A-1, table A-1 
 
Family evaluation of hospice care (FEHC) 
Symptom Management and End-of-Life Care; Accountability, Quality Improvement, and/or Sur-
veillance Measure 
 
Intellectual Property Owner: National Hospice and Palliative Care Organisation NHPCO 
Methodology: Responses to survey instrument. Family members of all patients enrolled in a hos-
pice program. This tool is only for family members of patients who died following care. 
Exclusions: Exclude patients who are not enrolled in a hospice program of have disenrolled from a 
hospice program. Live discharges are excluded. 
Data source/ Reporting: Family members of deceased patients (survey responses). 
 
Details on family evaluation survey: NQF (2009a), figure A-1, table A-1 
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No. Domain Subgroup Indicator Details/ Source 
30 End-of-life Dyspnea 
Assessment 
Dyspnea assessed on either of 
the last two visits before death 
American Medical Association and 
American Society of Clinical Oncology 
http://www.ama-
assn.org/ama1/pub/upload/mm/pcpi/palli
ative-care.pdf  
Measure #2 
31 End-of-life Dyspnea 
Treatment 
Dyspnea addressed on either of 
the last two visits before death 
American Medical Association and 
American Society of Clinical Oncology 
http://www.ama-
assn.org/ama1/pub/upload/mm/pcpi/palli
ative-care.pdf  
Measure #2 
 
Dyspnea Screening and Management  
Palliative and End of Life Care  
 
Measure Description  
Percentage of patients with advanced chronic or serious life threatening illnesses that are screened 
for dyspnea. For those that are diagnosed with moderate or severe dyspnea, a documented plan of 
care to manage dyspnea exists. 
 
Numerator  1. Patients who are screened for dyspnea.  
 
2. Patients who are screened for dyspnea and diagnosed with moderate or severe dyspnea, 
who have a documented plan of care* to manage dyspnea  
 
*A documented plan of care includes: a plan for treatment of dyspnea, including but not lim-
ited to: nonpharmacologic treatments (e.g. repositioning, improving air circulation, relaxation 
techniques) and pharmacologic methods (e.g. oxygen, opioids, anxiolytics) OR a statement 
about why no intervention is undertaken AND a plan for assessment including indication of 
reassessment time or interval  
Denominator Patients with incurable cancer, organ system failure, or severe progressive neurological condi-
tions (identified with ICD-9 code)  
AND  
Patients with a substantial risk of death within one year, based on the physician’s clinical 
judgment integrating the patients co-morbidities, health status, social and other factors (iden-
tified with CPT-II code)  
OR  
Patients with advanced disease whose goals of care prioritize comfort (identified with CPT-II 
code) 
Denominator Exc-
lusions 
None  
 
Measure Importance 
Relationship to desired outcome Assessment and treatment of symptoms such as dyspnea are deemed criti-
cal for palliative care. Dyspnea is a symptom frequently seen in the end of 
life population. Identification and treatment (if necessary) of dyspnea im-
proves quality of life at the end of life.  
Opportunity for Improvement  While no published data regarding a quality gap or variation in performance 
are available for this measure topic, the work group was in consensus that 
this is an aspect of care that is not regularly performed for all patients. 
Through implementation and testing of this measure, it is expected that we 
will be able to collect data that will help us demonstrate whether or not a 
gap in care or variation in performance exists  
Exclusion Justification This measure has no exclusions  
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